[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 299
1. Haddad LB, Scatton O, Randone B, Andraus W, Massault PP, Dousset B, Soubrane O: Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice. HPB (Oxford); 2009 May;11(3):203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice.
  • BACKGROUND: A pancreatic fistula (PF) is the most common complication after pancreaticoduodenectomy (PD), and its reported incidence varies from 2% to 28%.
  • The main indications for PD were pancreatic duct carcinoma in 52 patients (44.5%), ampullary carcinoma or adenoma in 18 (15.4%) and islet cell tumour in 11 (9.4%).
  • The medium delay between the pancreatic resection and reoperation was 10 days (range, 3-32 days).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2004 Jan;139(1):16-9 [14718268.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] World J Surg. 2003 Jun;27(6):709-14 [12732998.001]
  • [Cites] Arch Surg. 2006 Jun;141(6):574-9; discussion 579-80 [16785358.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):767-71, discussion 771-3 [16327486.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1117-23 [15931656.001]
  • [Cites] Arch Surg. 2005 Sep;140(9):849-54; discussion 854-6 [16172293.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] World J Surg. 2005 Feb;29(2):212-6 [15654661.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):951-9 [15585382.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):766-72; discussion 772-4 [15531229.001]
  • [Cites] World J Surg. 1999 Feb;23(2):164-71; discussion 171-2 [9880426.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):18-24 [9208956.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):176-9 [8689156.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1270-3 [7552016.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Br J Surg. 1994 Feb;81(2):265-9 [8156354.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):295-8 [7524375.001]
  • [Cites] Ann Surg. 1993 Sep;218(3):229-37; discussion 237-8 [8103982.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] Arch Surg. 1992 Aug;127(8):945-9; discussion 949-50 [1353671.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):521-4 [1350387.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):125-30; discussion 130-1 [1733360.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):39-47 [3276272.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] J Am Coll Surg. 2004 Aug;199(2):198-203 [15275873.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Arch Surg. 2003 Dec;138(12):1310-4; discussion 1315 [14662530.001]
  • [Cites] J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565 [12691930.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):57-65 [12496531.001]
  • [Cites] Br J Surg. 2002 Oct;89(10):1245-51 [12296891.001]
  • [Cites] Dig Surg. 2001;18(6):453-7; discussion 458 [11799295.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):117-20 [11044525.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):419-29 [10973392.001]
  • [Cites] J Gastrointest Surg. 2003 Jul-Aug;7(5):672-82 [12850681.001]
  • (PMID = 19590648.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2697888
  • [Keywords] NOTNLM ; pancreatic fistula / pancreatic resection / pancreaticoduodenectomy / postoperative complications
  •  go-up   go-down


2. Shiba H, Misawa T, Wakiyama S, Iida T, Ishida Y, Yanaga K: Pedunculated early ampullary carcinoma treated by ampullectomy: report of a case. J Gastrointest Cancer; 2010 Jun;41(2):138-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pedunculated early ampullary carcinoma treated by ampullectomy: report of a case.
  • CASE REPORT: A 30-year-old woman was admitted to our hospital for treatment of an ampullary tumor.
  • Upper gastrointestinal endoscopy revealed a pedunculated tumor in the ampulla of Vater with a diameter of 50 mm, which was biopsied and diagnosed as tubulovillous adenoma with moderate atypia.
  • DISCUSSION: Ampullectomy is an established method for ampullary tumor, but such a tumor with a long stalk is rare.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1993 May;128(5):515-20 [8098205.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):185-9 [12622430.001]
  • [Cites] Ann Surg. 1987 Nov;206(5):572-7 [3314748.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):239-44 [15368107.001]
  • [Cites] Surgery. 2000 Oct;128(4):694-701 [11015104.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Surg Today. 2008;38(5):440-4 [18560968.001]
  • [Cites] Radiology. 1990 May;175(2):455-61 [2183284.001]
  • [Cites] Surg Innov. 2004 Dec;11(4):255-63 [15756395.001]
  • (PMID = 20012229.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Bloomston M, Walker M, Frankel WL: Radical resection in signet ring carcinoma of the ampulla of Vater: report of an 11-year survivor. Am Surg; 2006 Feb;72(2):193-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical resection in signet ring carcinoma of the ampulla of Vater: report of an 11-year survivor.
  • Carcinomas of the ampulla of Vater are uncommon tumors but have a better prognosis than typical pancreatic cancers.
  • Signet ring features associated with poor differentiation traditionally confer a dismal prognosis in other gastrointestinal malignancies, particularly gastric cancer.
  • Signet cell ring morphology has only been described in a few ampullary carcinomas with all cases reporting short follow-up.
  • We describe a 58-year-old woman who presented with painless jaundice and a prominent ampulla of Vater by endoscopy.
  • She underwent pancreaticoduodenectomy and was found to have a 1.0 x 0.8 cm poorly differentiated carcinoma with prominent signet ring cell features arising from the ampulla of Vater and invading into the periampullary duodenum but sparing the pancreatic parenchyma.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Signet Ring Cell / surgery. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536256.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


Advertisement
4. Kim YK, Han YM, Kim CS: Usefulness of fat-suppressed T1-weighted MRI using orally administered superparamagnetic iron oxide for revealing ampullary carcinomas. J Comput Assist Tomogr; 2007 Jul-Aug;31(4):519-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of fat-suppressed T1-weighted MRI using orally administered superparamagnetic iron oxide for revealing ampullary carcinomas.
  • OBJECTIVE: To evaluate the value of adding fat-suppressed (FS) T1-weighted magnetic resonance imaging (MRI) with orally administered superparamagnetic iron oxide (SPIO) to the 3-dimensional dynamic MRI for revealing ampullary carcinomas.
  • MATERIALS: Twenty-five patients with ampullary carcinoma who underwent MRI with orally administered SPIO, including a FS T1-weighted fast low-angle shot (FLASH) sequence, a respiratory-triggered turbo spin-echo (RT-TSE) sequence, and the 3-phasic 3-dimensional dynamic images, were enrolled in this study.
  • CONCLUSIONS: Addition of the FS FLASH image using orally administered SPIO to the dynamic MRI is useful for revealing ampullary carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater. Common Bile Duct Neoplasms / diagnosis. Contrast Media. Ferric Compounds. Image Enhancement / methods. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882025.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 1K09F3G675 / ferric oxide
  •  go-up   go-down


5. Bulat C, Bîşca L, Stoian M: [Tumors of the ampulla of Vater--local or radical resection?]. Rev Med Chir Soc Med Nat Iasi; 2006 Jul-Sep;110(3):609-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumors of the ampulla of Vater--local or radical resection?].
  • [Transliterated title] Tumorile benigne ale ampulei lui Vater--rezecţie locală sau radicală?
  • Duodenal ampulla is a complex anatomical and histological site and a tumor may arise from one of three types of epithelium: duodenal mucosa, pancreatic duct and distal common bile duct.
  • Benign adenomas appear to be a frequent precursor of carcinoma of the ampulla of Vater, therefore, a local resection can lead to an under treated early cancer which would have benefited from a radical excision, with a much better long term result.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Duodenal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571553.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


6. Aparajita R, Gomez D, Verbeke CS, Menon KV: Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum. JOP; 2008;9(2):212-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum.
  • The diagnosis of these rare tumours is established on histopathological analysis following resection.
  • Coincidence of a biliary adenoma of the distal common bile duct and a synchronous adenocarcinoma of the peri-ampullary duodenum has never been reported in the literature.
  • CASE REPORT: We report a case of a papillary adenoma in the common bile duct in a 75-year-old female, who had synchronous invasive adenocarcinoma of the peri-ampullary duodenum.
  • CONCLUSION: Isolated papillary adenoma of the bile duct is extremely rare, and in this unusual case it coincided with a peri-ampullary duodenal adenocarcinoma.
  • However, this is a rare instance of an incidental finding within the distal bile duct following pancreaticoduodenectomy for curative treatment of a peri-ampullary adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Common Bile Duct / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326932.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Botsios D, Zacharakis E, Lambrou I, Tsalis K, Christoforidis E, Kalfadis S, Zacharakis E, Betsis D, Dadoukis I: Our local experience with the surgical treatment of ampullary cancer. Int Semin Surg Oncol; 2005 Aug 30;2:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Our local experience with the surgical treatment of ampullary cancer.
  • BACKGROUND: The aim of this study is to report the outcome after surgical treatment of 32 patients with ampullary cancers from 1990 to 1999.
  • METHODS: Twenty-one of them underwent pancreaticoduodenectomy and 9 local excision of the ampullary lesion.
  • RESULTS: When the final histological diagnosis was compared with the preoperative histological finding on biopsy, accurate diagnosis was preoperatively established in 24 patients.
  • Following local excision of the ampullary cancer, the survival rate at 3 and 5 years was 77.7% and 33.3% respectively.
  • CONCLUSION: In this series, local resection was a safe option in patients with significant co-morbidity or small ampullary tumors less than 2 cm in size, and was associated with satisfactory long-term survival rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1973-9 [10430380.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Am J Surg. 1989 Dec;158(6):593-6; discussion 596-7 [2589595.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):356-68 [7682052.001]
  • [Cites] Arch Surg. 1994 Oct;129(10):1075-80 [7944938.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Chirurg. 1993 Jun;64(6):476-82 [8359060.001]
  • [Cites] Leber Magen Darm. 1993 Jan;23(1):13-8, 21-3 [8445972.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):134-40 [8597506.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Eur J Surg Oncol. 1996 Aug;22(4):366-71 [8783654.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Surgery. 1986 Oct;100(4):716-23 [3764694.001]
  • [Cites] Acta Chir Scand. 1986 Aug-Sep;152:537-9 [3788399.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Br J Surg. 1987 Feb;74(2):116-8 [3815026.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):72-3 [3947884.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):46-52 [3966641.001]
  • [Cites] J R Coll Surg Edinb. 1982 May;27(3):154-7 [7108832.001]
  • [Cites] Endoscopy. 1981 Jul;13(4):154-6 [7250083.001]
  • (PMID = 16131399.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215507
  •  go-up   go-down


8. Murakami Y, Uemura K, Sasaki M, Morifuji M, Hayashidani Y, Sudo T, Sueda T: Duodenal cancer arising from the remaining duodenum after pylorus-preserving pancreatoduodenectomy for ampullary cancer in familial adenomatous polyposis. J Gastrointest Surg; 2005 Mar;9(3):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal cancer arising from the remaining duodenum after pylorus-preserving pancreatoduodenectomy for ampullary cancer in familial adenomatous polyposis.
  • We herein report a rare occurrence of duodenal cancer arising from the remaining duodenum after pylorus-preserving pancreatoduodenectomy for ampullary cancer in familial adenomatous polyposis (FAP).
  • During the current admission, the patient was diagnosed with adenocarcinoma in the Vater's ampulla using imaging and pathological examinations.
  • [MeSH-minor] Adult. Ampulla of Vater / pathology. Cholangiopancreatography, Endoscopic Retrograde / methods. Duodenoscopy / methods. Female. Follow-Up Studies. Humans. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Pylorus. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Dis Colon Rectum. 1990 Aug;33(8):639-42 [2165452.001]
  • [Cites] Lancet. 1995 Apr 1;345(8953):855-6 [7898240.001]
  • [Cites] J R Soc Med. 1991 Aug;84(8):476-8 [1653358.001]
  • [Cites] Lancet. 1988 May 21;1(8595):1149-51 [2896968.001]
  • [Cites] Int J Colorectal Dis. 1998;13(1):39-42 [9548099.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):709-10 [7962621.001]
  • [Cites] Br J Surg. 1998 May;85(5):665-8 [9635818.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Gut. 1997 Jun;40(6):716-9 [9245923.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):671-5 [12399055.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 15749602.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Cortes A, Sauvanet A, Bert F, Janny S, Sockeel P, Kianmanesh R, Ponsot P, Ruszniewski P, Belghiti J: Effect of bile contamination on immediate outcomes after pancreaticoduodenectomy for tumor. J Am Coll Surg; 2006 Jan;202(1):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The distribution of tumors was comparable except for ampullary carcinoma, which was more frequent in group B+ patients (p = 0.001).
  • During PD for ampullary carcinoma or after interventional biliary endoscopy, a specific antibioprophylaxis should be evaluated.
  • [MeSH-major] Ampulla of Vater. Bile / microbiology. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377502.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Palanivelu C, Jani K, Senthilnathan P, Parthasarathi R, Rajapandian S, Madhankumar MV: Laparoscopic pancreaticoduodenectomy: technique and outcomes. J Am Coll Surg; 2007 Aug;205(2):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The procedure could be completed laparoscopically with tumor-free margins in all patients, including patients with ampullary carcinoma (n = 24), pancreatic cystadenocarcinoma (n = 4), pancreatic head adenocarcinoma (n = 9), low common bile duct cancer (n = 3), and two patients with chronic pancreatitis with a suspicious mass lesion in the head of pancreas.
  • Five-year actuarial survival rates for all patients with malignancy, ampullary adenocarcinoma, pancreatic cystadenocarcinoma, pancreatic head adenocarcinoma, and common bile duct adenocarcinoma are 32%, 30.7%, 33.3%, 19.1%, and 50%, respectively.
  • Localized malignant lesions, irrespective of histopathology, are particularly amenable to this approach.
  • [MeSH-major] Duodenal Neoplasms / surgery. Laparoscopy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660068.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Grobmyer SR, Stasik CN, Draganov P, Hemming AW, Dixon LR, Vogel SB, Hochwald SN: Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla. J Am Coll Surg; 2008 Mar;206(3):466-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla.
  • STUDY DESIGN: We retrospectively reviewed our experience with ampullectomy in 29 patients with a preoperative benign histologic diagnosis over 15 years (1991 to 2006).
  • Ampullary adenomatous neoplasms were present in 89% of patients.
  • Preoperative biopsy and intraoperative frozen section failed to identify carcinoma in four patients.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Humans. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308217.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Yeh CC, Jeng YM, Ho CM, Hu RH, Chang HP, Tien YW: Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age. World J Surg; 2010 Dec;34(12):2945-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age.
  • BACKGROUND: Although pancreaticoduodenectomy (PD) provides the best chance of survival for elderly patients with ampullary carcinoma, it is associated with considerable surgical risk.
  • The aim of the present study was to compare the benefits and risks of pancreaticoduodenectomy as a treatment of ampullary carcinoma between young and elderly patients.
  • Comparison of the biological aggressiveness of ampullary cancer between old and younger patients was also performed by immunohistochemical study of several prognostic biological markers, including MUC1, MUC2, CK17, and CDX2.
  • RESULTS: For patients in whom ampullary carcinoma was presumed resectable preoperatively, actuarial survival was significantly poorer in 55 elderly patients because 9 of them did not have PD (the other 46 had PD) than in 101 younger patients (all had PD).
  • There were no significant differences in MUC1, CK17, MUC2, and CDX2 immunohistochemical staining of ampullary carcinomas between elderly and young patients.
  • CONCLUSIONS: Our data support the conclusion that ampullary cancers in elderly patients should be treated as aggressively as in younger patients.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / mortality

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):201-10 [15615658.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • [Cites] World J Surg. 2006 Nov;30(11):1992-2001; discussion 2002-3 [16957825.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):426-34; discussion 434-7 [7574924.001]
  • [Cites] Br J Cancer. 1997;75(4):593-6 [9052416.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Am J Surg. 1991 Dec;162(6):532-5; discussion 535-6 [1670220.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):971-80 [16244798.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Br J Surg. 1998 May;85(5):607-10 [9635804.001]
  • [Cites] Arch Surg. 2003 Oct;138(10):1061-7 [14557121.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):359-67 [15725805.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1811-8 [15774774.001]
  • (PMID = 20714897.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Kiil J, Henneberg EW: [Performing major upper abdominal operations in a low-volume hospital: is it possible?]. Ugeskr Laeger; 2006 Apr 10;168(15):1529-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The five-year survival rate based on death from cancer was 37% and from all causes 32%.
  • The five-year survival rate based on death from was cancer 55% and from all causes 37%.
  • The survival rate based on death from cancer was 77% and from all causes was 54% after five years for cancer of the ampulla of Vater, and 27% and 31% after three years for pancreatic head carcinoma.
  • CONCLUSION: Major gastric and pancreatic operations can be performed in a low-volume hospital with satisfactory results.
  • [MeSH-major] Digestive System Surgical Procedures. Esophageal Neoplasms / surgery. Health Facility Size. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Surgery Department, Hospital / statistics & numerical data


14. Gaujoux S, Cortes A, Couvelard A, Noullet S, Clavel L, Rebours V, Lévy P, Sauvanet A, Ruszniewski P, Belghiti J: Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery; 2010 Jul;148(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy.
  • BACKGROUND: Pancreatic fistula (PF) after pancreatoduodenectomy (PD) remains a challenging problem.
  • The only commonly accepted risk factor is the soft consistency of the pancreatic remnant.
  • All data, including commonly accepted risk factors for PF and PF defined according to the International Study Group of Pancreatic Fistula, were collected prospectively.
  • On the pancreatic margin, a score of fibrosis and a score of fatty infiltration were assessed by a pathologist blinded to the postoperative course.
  • In univariate analysis, male sex, age greater than 58 years, body mass index (BMI) > or =25 kg/m(2), pre-operative high blood pressure, operation for nonintraductal papillary and mucinous neoplasm (IPMN) disease and for ampullary carcinoma, operative time, blood loss, soft consistency of the pancreatic remnant, absence of pancreatic fibrosis, and presence of fatty infiltration of the pancreas were associated with a greater risk of PF.
  • In a multivariate analysis, only BMI > or =25 kg/m(2), absence of pancreatic fibrosis, and presence of fatty pancreas were significant predictors of PF.
  • CONCLUSION: The presence of an increased BMI, the presence of fatty pancreas, and the absence of pancreatic fibrosis as risk factors of PF allows a more precise and objective prediction of PF than the consistency of pancreatic remnant alone.
  • [MeSH-major] Body Mass Index. Pancreas / pathology. Pancreatic Fistula / etiology. Pancreaticoduodenectomy / adverse effects. Postoperative Complications / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Mosby, Inc.
  • (PMID = 20138325.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Morla D, Alazemi S, Lichtstein D: Stauffer's syndrome variant with cholestatic jaundice: a case report. J Gen Intern Med; 2006 Jul;21(7):C11-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholestasis is a common feature of several malignant diseases, including pancreatic, hepatic, gallbladder, and ampullary carcinomas.
  • Stauffer's syndrome is a rare paraneoplastic manifestation of renal cell carcinoma (RCC) that is characterized by elevated alkaline phosphatase, erythrocyte sedimentation rate, alpha-2-globulin, and gamma-glutamyl transferase, thrombocytosis, prolongation of prothrombin time, and hepatosplenomegaly, in the absence of hepatic metastasis and jaundice.
  • This case illustrates the protean manifestations of RCC, and the importance of considering Stauffer's syndrome and its variant in the differential diagnosis of anicteric and icteric cholestasis, which may allow early recognition and treatment of an underlying malignancy.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Jaundice, Obstructive / etiology. Kidney Neoplasms / diagnosis. Paraneoplastic Syndromes / etiology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1992 Jul;103(1):330-2 [1612341.001]
  • [Cites] Semin Urol Oncol. 1996 Nov;14(4):216-22 [8946620.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Mar;9(3):311-4 [9096437.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):424-30 [9247285.001]
  • [Cites] Cancer. 1971 Nov;28(5):1165-77 [5125665.001]
  • [Cites] Ann Med Interne (Paris). 2003 May;154(3):171-5 [12910044.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Nov;1(6):480-3 [15017648.001]
  • [Cites] Int J Urol. 2005 Aug;12(8):757-9 [16174051.001]
  • (PMID = 16808761.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1924715
  •  go-up   go-down


16. Perrone G, Santini D, Verzì A, Vincenzi B, Borzomati D, Vecchio F, Coppola R, Antinori A, Magistrelli P, Tonini G, Rabitti C: COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. J Clin Pathol; 2006 May;59(5):492-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.
  • To data, there have been few clinicopathological studies on COX-2 expression in human ampullary carcinoma and no data have been reported about its relation with tumour angiogenesis.
  • OBJECTIVE: To investigate by immunohistochemistry the expression of COX-2 and the angiogenesis process in a series of primary untreated ampullary carcinomas.
  • METHODS: Tissue samples from 40 archival ampullary carcinomas were analysed for COX-2, vascular endothelial growth factor (VEGF), and an endothelial cell marker von Willebrand factor (vWF) by immunohistochemistry, using specific antibodies.
  • CONCLUSIONS: COX-2 is highly expressed in ampullary carcinomas.
  • This suggests an involvement of the COX-2 pathway in ampullary tumour associated angiogenesis, providing a rationale for targeting COX-2 in the treatment of ampullary cancer.
  • [MeSH-major] Ampulla of Vater. Carcinoma / enzymology. Common Bile Duct Neoplasms / enzymology. Cyclooxygenase 2 / analysis. Neovascularization, Pathologic / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Jun;25(2):333-48 [9229576.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1625-9 [9134996.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):362-6 [9443418.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):982-90 [15705899.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2637-45 [11135226.001]
  • [Cites] Langenbecks Arch Surg. 2001 Apr;386(3):163-71 [11382316.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 7;286(5):923-8 [11527387.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1127-35 [11677205.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2001 Sep;65(3):123-31 [11728162.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):908-14 [11866451.001]
  • [Cites] Br J Pharmacol. 2002 May;136(2):287-95 [12010778.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):50081-6 [12401798.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):218-24 [12692419.001]
  • [Cites] Biomed Pharmacother. 2003 Dec;57(10):463-70 [14637390.001]
  • [Cites] J Cell Physiol. 2004 Jul;200(1):20-30 [15137054.001]
  • [Cites] Cancer Lett. 2004 May 28;208(2):227-34 [15142682.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):475-82 [6180207.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1403-7 [2449947.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Epidemiology. 1994 Mar;5(2):138-46 [8172988.001]
  • [Cites] Ann N Y Acad Sci. 1995 Mar 27;752:246-56 [7538737.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):139-55 [8534863.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • (PMID = 16489179.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A; 0 / von Willebrand Factor; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC1860297
  •  go-up   go-down


17. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT: Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg; 2006 Sep-Oct;10(8):1106-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between July 1994 and December 2004, 222 PD (78% pylorus preserving, 19% Whipple, and 3% total pancreatectomy) were performed for malignant disease.
  • Long-term survival was analyzed in 165 patients with pancreatic (n = 110), ampullary (n = 33), or distal bile (n = 22) duct cancer using univariate (log-rank) and multivariate (Cox regression) methods.
  • Five-year survival rates were 15% in cancer of the pancreatic head, 22% in ampullary cancer, and 24% in distal bile duct cancer (P = 0.02).
  • Univariate survival analysis of the 110 patients with cancer of the pancreatic head revealed that a histologically undifferentiated tumor (P = 0.05) and positive resection margins (P = 0.02) were associated with a poorer survival.
  • In case of tumor adherence or infiltration, combined resection of the pancreatic head and the vein should always be considered in the absence of other contraindications for resection.
  • [MeSH-major] Mesenteric Veins / pathology. Mesenteric Veins / surgery. Pancreatic Neoplasms. Pancreaticoduodenectomy / methods. Portal Vein / pathology. Portal Vein / surgery. Vascular Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Morbidity / trends. Neoplasm Invasiveness. Postoperative Period. Prospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Nov;9(8):1080-6; discussion 1086-7 [16269378.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):120-9 [11574081.001]
  • [Cites] J Vasc Interv Radiol. 2002 Aug;13(8):805-14 [12171984.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Pancreas. 2004 Apr;28(3):289-92 [15084973.001]
  • [Cites] Surgery. 1995 Jan;117(1):50-5 [7809836.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Chirurg. 2000 Jul;71(7):803-7 [10986602.001]
  • [Cites] Surgery. 2001 Feb;129(2):158-63 [11174708.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1089-95 [14675720.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1191-204; discussion 1204-6 [16332474.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] World J Surg. 1999 Sep;23(9):926-9 [10449822.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5 [8554135.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):201-8 [14769305.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):293-8 [15273554.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):786-95 [11088073.001]
  • [Cites] Br J Surg. 1998 May;85(5):611-7 [9635805.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):154-62 [8597509.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1190-3 [7953357.001]
  • [Cites] Surgery. 1991 Apr;109(4):481-7 [1848949.001]
  • [Cites] Ann Surg. 1995 Dec;222(6):711-8 [8526577.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1002-5 [11571964.001]
  • [Cites] J Gastrointest Surg. 2003 Feb;7(2):209-19 [12600445.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):342-7; discussion 347-9 [8813262.001]
  • (PMID = 16966029.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


18. Ouaïssi M, Sielezneff I, Alves A, Pirro N, Heyries L, Robitail S, Consentino B, Payan MJ, Valleur P, Panis Y, Sastre B: [Long term outcome following 26 surgical ampullectomies]. Ann Chir; 2006 May;131(5):322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Résultat à long terme de 26 ampullectomies chirurgicales.
  • BACKGROUND: Pancreaticoduodenectomy (PD) is the standard surgical treatment for malignant ampullomas but is still associated with a mortality and morbidity still ranging from 0 to 10% and from 15 to 40%, respectively.
  • Ampullectomy is an alternative to PD for benign ampulloma or, in high-risk patients, for invasive carcinoma.
  • CONCLUSION: Ampullectomy is a good alternative to PD in case of benign or non-invasive malignant ampullary lesion, including in selected cases of FAP.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Adult. Aged. Carcinoma in Situ / surgery. Cause of Death. Common Bile Duct Diseases / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Somatostatinoma / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615931.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Chong VH, Telisinghe PU, Yapp SK, Jalihal A: Biliary strictures secondary to tuberculosis and early ampullary carcinoma. Singapore Med J; 2009 Mar;50(3):e94-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary strictures secondary to tuberculosis and early ampullary carcinoma.
  • Malignancies are important causes and are often unresectable at the time of diagnosis.
  • We report a 67-year-old man with unexpected findings of obstructive jaundice secondary to biliary TB and an early ampullary tumour.
  • [MeSH-minor] Aged. Ampulla of Vater / pathology. Biliary Tract Surgical Procedures. Constriction, Pathologic / pathology. Humans. Male. Risk Factors

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352560.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


20. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M: CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paraffin-embedded sections of various adenocarcinomas (13 colonic, 11 mucinous ovarian, 5 serous ovarian, 8 pancreatic, 6 ampullary, 12 gastric, 5 esophageal, 10 endometrial, 29 breast, and 55 lung) and 29 additional lung carcinomas (nonadenocarcinomas) were immunostained with antibodies to CDX2 protein, cytokeratin 7 (CK7), and cytokeratin 20 (CK20).
  • Esophageal, gastric, and ampullary adenocarcinomas showed variable immunoreactivity for CDX2.
  • All breast, nonmucinous ovarian, and most endometrial and pancreatic adenocarcinomas showed no immunoreactivity for CDX2.
  • Of these, 5 (4 adenocarcinomas and 1 large cell carcinoma) were reactive for TTF-1.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):249-50 [16785799.001]
  • (PMID = 15722794.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


21. Geraci G, Pisello F, Arnone E, Modica G, Sciumè C: Endoscopic cytology in biliary strictures. Personal experience. G Chir; 2008 Oct;29(10):403-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The differential diagnosis between malignant and benign biliary strictures is the cornerstone of the management of jaundiced patients.
  • The aim of our study is to define the role of cytology of the bile withdrawn during endoscopic retrograde cholangiopancreatography (ERCP), to reach a diagnosis of the nature of biliary stricture.
  • RESULTS: Diagnosis was made in only 40 of 65 patients (61.5%) and no epithelial lining cells of the biliary tree was found in the remaining 25 patients (38.5%).
  • The presence of neoplasm in the pancreato-biliary tract was excluded (absence of malignant cells) in 25 of 40 diagnostic exams (62.5%).
  • During follow-up only 7 of these 25 patients resulted in having a benign disease (true negatives 28%) while the remaining 18 cases were diagnosed with malignant neoplasm of the pancreato-biliary tract (false negatives 72%).
  • Nine of 14 with positive cytology for carcinoma were diagnosed with cholangiocarcinoma (65%), 4 with pancreatic (28%) and 1 with ampullary carcinoma.
  • Of 25 non-diagnostic samples, 5 (20%) resulted as benign, 20 (80%) as malignant.
  • The statistical analysis by chi-square test allowed us to conclude that bile cytology, if diagnostic, is significantly valid in identifying carcinoma of the pancreato-biliary tract (p<0.05) instead, considering the high rate of non diagnostic samples, its meaning is limited (p=0.09).
  • DISCUSSION: Exfoliative cytology of bile samples obtained during ERCP is easier and less invasive method to determine the diagnosis of biliary strictures, but due to its low sensibility, varying from 6 to 63%, it doesn't appear accurate to establish a definite diagnosis; the stricture dilatation before the withdrawal increases the diagnostic sensibility and accuracy of the cytological exam.
  • Negative results does not exclude malignant disease, however, if positive, it is considered diagnostic (positive predictive value 100%).
  • [MeSH-major] Bile / cytology. Bile Duct Neoplasms / pathology. Cholangiocarcinoma / pathology. Cholangiopancreatography, Endoscopic Retrograde. Jaundice, Obstructive / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Bile Duct Diseases / pathology. Biopsy, Needle. Chi-Square Distribution. Constriction, Pathologic / diagnosis. Diagnosis, Differential. Drainage / instrumentation. Drainage / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Stents. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947461.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Corbo V, Ritelli R, Barbi S, Funel N, Campani D, Bardelli A, Scarpa A: Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. PLoS One; 2010;5(9):e12653
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.
  • METHODOLOGY/PRINCIPAL FINDINGS: We conducted a DNA-sequence analysis of a selected set of 35 kinase genes in a panel of 52 pancreatic exocrine neoplasms, including 36 pancreatic ductal adenocarcinoma, and 16 ampulla of Vater cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Common Bile Duct Neoplasms / genetics. Mutation. Pancreatic Neoplasms / genetics. Protein Kinases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / enzymology. Base Sequence. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Molecular Sequence Data


23. Tien YW, Yeh CC, Wang SP, Hu RH, Lee PH: Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms? J Gastrointest Surg; 2009 Sep;13(9):1666-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms?
  • BACKGROUND: Many specialists justify pancreaticoduodenectomy (PD) for pancreatic head neoplasms with suspected but unproven malignance (blind-PD).
  • Our aim in this study was to determine whether blind-PD is also justified for ampullary neoplasms.
  • METHODS: We retrospectively reviewed the records of all patients with presumed resectable ampullary neoplasms treated at the National Taiwan University Hospital from 1998 to 2008.
  • RESULTS: Of the 84 patients without a preoperative tissue diagnosis of malignance, 64 had blind-PD and 20 had ampullectomy (AMP) with intraoperative frozen section.
  • Final pathological diagnosis was benign in ten of 64 blind-PD-treated patients.
  • CONCLUSIONS: Our data support a selective use of blind-PD because (1) a significant portion (65%) of benign ampullary neoplasms can be safely and effectively treated by AMP, (2) blind-PD does not treat ampullary cancer at earlier stage, and (3) blind-PD is associated with significantly more complications and significantly longer hospital stay than AMP.
  • However, blind-PD is strongly recommended for patients with large ampullary neoplasms (>3 cm in diameter), with jaundice, or with malignant endoscopic appearance.
  • [MeSH-major] Ampulla of Vater / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Hospital Mortality / trends. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Preoperative Care. Probability. Registries. Retrospective Studies. Risk Assessment. Sphincterotomy, Endoscopic. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] World J Surg. 1999 Feb;23(2):158-62; discussion 162-3 [9880425.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Sep;24(5):617-22 [19122504.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):948-51 [9240132.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] South Med J. 1989 Jul;82(7):917-20 [2665132.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):239-43 [12145603.001]
  • [Cites] J Gastrointest Surg. 2006 Sep-Oct;10(8):1140-3 [16966033.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):32-41 [12704445.001]
  • [Cites] Ann Chir. 2004 Mar;129(2):73-8 [15050176.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):971-80 [16244798.001]
  • [Cites] Am Surg. 2004 Jan;70(1):6-10; discussion 11-2 [14964538.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1300-6 [16332486.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):1855-61 [18415651.001]
  • [Cites] Pancreas. 1995 Oct;11(3):283-8 [8577683.001]
  • [Cites] Endoscopy. 2003 May;35(5):402-6 [12701011.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1188-96 [1746684.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] Gastrointest Endosc. 1990 Nov-Dec;36(6):588-92 [2279648.001]
  • [Cites] Endoscopy. 2005 May;37(5):444-8 [15844023.001]
  • (PMID = 19557483.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Pedicone R, Adham M, Hervieu V, Lombard-Bohas C, Guibal A, Scoazec JY, Chayvialle JA, Partensky C: Long-term survival after pancreaticoduodenectomy for endocrine tumors of the ampulla of Vater and minor papilla. Pancreas; 2009 Aug;38(6):638-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after pancreaticoduodenectomy for endocrine tumors of the ampulla of Vater and minor papilla.
  • OBJECTIVE: Endocrine tumors of the ampullary region are rare, and accurate indications for their management are lacking.
  • METHOD: We reviewed all patients who submitted to a pancreaticoduodenectomy for ampullary endocrine tumors between 1982 and 2003 in our center.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Pancreatic Ductal / surgery. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531971.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Liu Y, Lu Z, Zou DW, Jin ZD, Liu F, Li SD, Zhan XB, Zhang WJ, Wu RP, Yao YZ, Yang L, Li Z: Intraluminal implantation of radioactive stents for treatment of primary carcinomas of the peripancreatic-head region: a pilot study. Gastrointest Endosc; 2009 May;69(6):1067-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients diagnosed with bile-duct, pancreatic-head, and ampullary carcinomas have a poor prognosis.
  • DESIGN AND SETTING: Patients with inoperable extrahepatic bile-duct (n = 2), pancreatic-head (n = 6), or ampullary (n = 3) carcinomas were treated by intraluminal implantation of radioactive stents designed according to a computerized treatment-planning system.
  • For pancreatic carcinoma, the combination of radioactive CBD and pancreatic duct (PD) stents or only a radioactive PD stent was chosen according to the tumor position.
  • CONCLUSIONS: The combination of radioactive stents and metallic and/or plastic stents was technically feasible and tolerable in patients with advanced tumors around the pancreatic-head area.
  • [MeSH-major] Ampulla of Vater. Brachytherapy / instrumentation. Common Bile Duct Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Pancreatic Ducts. Pancreatic Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Equipment Design. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Radiometry. Survival Analysis. Therapy, Computer-Assisted. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243771.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


26. Boix J, Lorenzo-Zúñiga V, Moreno de Vega V, Domènech E, Gassull MA: Endoscopic resection of ampullary tumors: 12-year review of 21 cases. Surg Endosc; 2009 Jan;23(1):45-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of ampullary tumors: 12-year review of 21 cases.
  • This study aimed to evaluate the outcome of endoscopic resection for ampullary tumors at a single center.
  • METHODS: All ampullary tumors without macroscopic features of malignancy identified by the endoscopic retrograde cholangiopancreatography (ERCP) from January 1995 to February 2007 were included in the study.
  • RESULTS: Of the 21 patients (9 men and 12 women; mean age, 67.2 +/- 14.3 years) evaluated, 11 had adenoma (7 had low-grade dysplasia [LGD] and 4 had high-grade dysplasia [HGD]), and 10 had carcinoma.
  • After papillectomy, 15 patients underwent Whipple procedures (endoscopic failure, 74.1%), including 3 patients with extensive intraductal growth (complete removal of the lesion impossible), 9 patients with carcinoma beyond the mucosal layer, and 3 patients with recurrence treated surgically.
  • CONCLUSIONS: In the hands of an experienced endoscopist, endoscopic papillectomy is a clinically effective treatment for ampullary tumors without invasive neoplasia.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Carcinoma / surgery. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct Neoplasms / surgery. Sphincterotomy, Endoscopic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2006 May;38(5):521-5 [16767591.001]
  • [Cites] Scand J Gastroenterol. 2000 Apr;35(4):337-44 [10831254.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Scand J Gastroenterol. 1996 Apr;31(4):376-82 [8726307.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):367-70 [16111953.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):239-43 [12145603.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2005 Jul;15(3):431-54, viii [15990050.001]
  • [Cites] Gastrointest Endosc. 1997 Mar;45(3):251-60 [9087831.001]
  • [Cites] J Gastroenterol. 2006 May;41(5):483-90 [16799891.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):1163-72 [8475992.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1227-31 [10586341.001]
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):292-301 [16427938.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):789-91 [16650539.001]
  • [Cites] Gastrointest Endosc. 2001 Aug;54(2):202-8 [11474391.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):757-64 [15557951.001]
  • [Cites] Gastrointest Endosc. 2004 Oct;60(4):544-50 [15472676.001]
  • [Cites] Surg Endosc. 2003 Oct;17(10):1514-20 [12915975.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • (PMID = 18398649.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Mizuno T, Ishizaki Y, Ogura K, Yoshimoto J, Kawasaki S: Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater. Br J Surg; 2006 Feb;93(2):221-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater.
  • BACKGROUND: The aim of this study was to assess the impact of immunohistochemically identified lymph node metastasis on survival in patients with carcinoma of the ampulla of Vater.
  • METHODS: Three hundred and twenty-six regional lymph nodes dissected from pancreatoduodenectomy specimens from 25 patients with ampulla of Vater carcinoma were immunostained with anticytokeratin antibody (CAM 5.2).
  • CONCLUSION: Immunostaining of dissected lymph nodes adds additional information to data obtained by conventional haematoxylin and eosin staining when determining the prognosis of patients with carcinoma of the ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / secondary. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 16363020.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Ahmadi A, Draganov P: Endoscopic mucosal resection in the upper gastrointestinal tract. World J Gastroenterol; 2008 Apr 7;14(13):1984-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EMR was originally described as a therapy for early gastric cancer.
  • Recently its use has expanded as a therapeutic option for ampullary masses, colorectal cancer, and large colorectal polyps.
  • [MeSH-minor] Animals. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Gastroenterology / methods. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Precancerous Conditions

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Gut. 2001 Feb;48(2):225-9 [11156645.001]
  • [Cites] Endoscopy. 2001 Feb;33(2):196 [11272228.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):221-6 [11293753.001]
  • [Cites] Endoscopy. 2001 Aug;33(8):709-18 [11490390.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2001 Jul;11(3):479-88, vi [11778749.001]
  • [Cites] Surg Today. 2001;31(12):1100-3 [11827193.001]
  • [Cites] Hepatogastroenterology. 1994 Aug;41(4):380-3 [7959576.001]
  • [Cites] Gastrointest Endosc. 1995 May;41(5):475-80 [7615226.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1995 Jul;5(3):537-47 [7582580.001]
  • [Cites] Gut. 1997 Jan;40(1):123-7 [9155589.001]
  • [Cites] Endoscopy. 1997 Jun;29(5):380-3 [9270919.001]
  • [Cites] Dis Esophagus. 1997 Jul;10(3):190-5 [9280078.001]
  • [Cites] Gut. 1997 Sep;41(3):281-4 [9378378.001]
  • [Cites] Endoscopy. 1997 Oct;29(8):751-3 [9427496.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Mar;25(4):476-83 [9530352.001]
  • [Cites] Surgery. 1998 Apr;123(4):432-9 [9551070.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):16-23; discussion 23-5 [9869753.001]
  • [Cites] Surgery. 1999 Feb;125(2):148-54 [10026747.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):251-6 [10425422.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40 [10493489.001]
  • [Cites] AMA Arch Surg. 1955 Jan;70(1):120-2 [13217613.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):506-14 [15812401.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):311-21 [15863379.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):819-22 [10570343.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2177-84 [11007214.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4490-8 [16002839.001]
  • [Cites] Endoscopy. 2005 Nov;37(11):1111-5 [16281141.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):871-87 [16338647.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):927-40 [16338650.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6650-5 [16425359.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):847-52 [16650552.001]
  • [Cites] Colorectal Dis. 2006 Jul;8(6):497-500 [16784470.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Jun;16(3):137-40 [16804454.001]
  • [Cites] Scand J Gastroenterol. 2006 Sep;41(9):1105-9 [16938725.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(5):867-76 [16997166.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):24-9 [17252456.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):41-5 [17252459.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):236-8 [17311646.001]
  • [Cites] Postgrad Med J. 2007 Jun;83(980):367-72 [17551066.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Gastrointest Endosc. 2007 Oct;66(4):660-6; quiz 767, 769 [17905005.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jul;22(1):1-6 [12103364.001]
  • [Cites] Endoscopy. 2002 Aug;34(8):604-10 [12173079.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):513-6 [12297766.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1085-91 [12362099.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):2998-3006 [12492182.001]
  • [Cites] Gastrointest Endosc. 2003 Feb;57(2):165-9 [12556777.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):567-79 [12665775.001]
  • [Cites] Gastrointest Endosc. 2003 Jun;57(7):854-9 [12776032.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):167-75 [12872081.001]
  • [Cites] Endoscopy. 2003 Nov;35(11):973-4 [14606024.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):258-63 [15017666.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):776-81 [15326572.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):782-7 [15326573.001]
  • [Cites] Hepatogastroenterology. 1990 Aug;37(4):408-10 [2170256.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):58-62 [8454147.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):347-55 [8385441.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):455-61 [8261988.001]
  • [Cites] Gastrointest Endosc. 1994 Mar-Apr;40(2 Pt 1):207-12 [8013823.001]
  • [Cites] Dis Colon Rectum. 1994 Nov;37(11):1108-11 [7956578.001]
  • (PMID = 18395896.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 70
  • [Other-IDs] NLM/ PMC2701517
  •  go-up   go-down


29. Kawakami H, Kuwatani M, Onodera M, Hirano S, Kondo S, Nakanishi Y, Itoh T, Asaka M: Primary acinar cell carcinoma of the ampulla of Vater. J Gastroenterol; 2007 Aug;42(8):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the ampulla of Vater.
  • Acinar cell carcinoma of the pancreatobiliary system is a relatively rare malignant neoplasm arising usually in the pancreatic parenchyma.
  • We experienced a 68-year-old woman who presented with obstructive jaundice due to an ampullary mass 1.0 cm in diameter, detected by abdominal computed tomography and endoscopic examination.
  • The patient underwent a curative surgical operation, and histopathological examination revealed that the tumor was confined to the ampulla of Vater with no continuity to the pancreatic parenchyma.
  • The tumor cells showed acinar or tubular arrangement with eosinophilic to basophilic granular cytoplasm, findings identical to those of acinar cell carcinoma of the pancreas.
  • From these findings, we concluded that the tumor was primary acinar cell carcinoma arising in the ampulla of Vater, probably originating from heterotopic pancreatic tissue.
  • This is the first reported case of primary acinar cell carcinoma in the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Acinar Cell / diagnosis. Common Bile Duct Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Endosonography. Female. Follow-Up Studies. Humans. Middle Aged. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] Dig Surg. 2005;22(5):377-9 [16432300.001]
  • [Cites] Arch Pathol Lab Med. 1994 May;118(5):568-71 [8192567.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):121-3 [11154509.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):101-7 [9020300.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):449-51 [12055683.001]
  • (PMID = 17701134.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS, Tan BR: Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford); 2010 Aug;12(6):418-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with histologically proven BTCs, including cholangiocarcinoma or gallbladder and ampullary carcinomas, were treated with a maximum of nine cycles of intravenous (i.v.) gemcitabine at 1000 mg/m(2) over 30 min on days 1 and 8 with i.v. carboplatin dosed at an area-under-the-curve (AUC) of 5 over 60 min on day 1 of a 21-day cycle.
  • RESULTS: A total of 48 patients with advanced BTCs (35 cholangiocarcinoma, 12 gallbladder and 1 ampullary cancer) were enrolled.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):783-9 [11462924.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1833-8 [11576836.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4089-91 [11600613.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Cancer. 1974 Jan;33(1):193-7 [4272473.001]
  • [Cites] Br J Surg. 1974 Feb;61(2):98-100 [4361236.001]
  • [Cites] Ann Surg. 1982 Mar;195(3):270-3 [7059239.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):965-9 [6235908.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1245-8 [6092556.001]
  • [Cites] Ann Surg. 1988 Feb;207(2):120-5 [2829760.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Surg Clin North Am. 1990 Dec;70(6):1429-47 [2174191.001]
  • [Cites] Arch Surg. 1993 Aug;128(8):871-7; discussion 877-9 [8393652.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):607-9 [8363992.001]
  • [Cites] J Surg Oncol. 1994 Apr;55(4):239-45 [8159005.001]
  • [Cites] Am J Clin Oncol. 1994 Jun;17(3):223-6 [8192106.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):931-4 [9625849.001]
  • [Cites] Oncology. 1999 Apr;56(3):177-80 [10202270.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):68-73 [15709089.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1030-4 [15990005.001]
  • [Cites] BMC Cancer. 2005;5:61 [15949047.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):647-53 [16142487.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4699-707 [16966687.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):134-41 [17207911.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 6;99(11):847-57 [17551145.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3702-8 [18669455.001]
  • [Cites] Clin Breast Cancer. 2008 Oct;8(5):425-31 [18952556.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):371-7 [19142638.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • (PMID = 20662793.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00660140
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC3028583
  •  go-up   go-down


31. Wu SD, Su Y, Fan Y, Zhang ZH, Wang HL, Kong J, Tian Y: Relationship between intraduodenal peri-ampullary diverticulum and biliary disease in 178 patients undergoing ERCP. Hepatobiliary Pancreat Dis Int; 2007 Jun;6(3):299-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between intraduodenal peri-ampullary diverticulum and biliary disease in 178 patients undergoing ERCP.
  • BACKGROUND: The presence of intraduodenal peri-ampullary diverticulum is often observed during upper digestive tract barium meal studies and endoscopic retrograde cholangiopancreatography (ERCP).
  • This study was undertaken to further test this notion and ascertain the relationship between intraduodenal peri-ampullary diverticulum and biliary disease, especially the formation of bile duct pigment stones.
  • They were divided into 6 groups according to the category of biliary disease, and the incidence rates of intraduodenal peri-ampullary diverticulum were calculated.
  • RESULTS: There were 44 patients with intraduodenal peri-ampullary diverticulum in 81 patients with primary bile duct pigment stones (54.32%), 4 in 8 patients with bile duct stones and gallbladder stones (50%), 7 in 33 patients with bile duct stones secondary to gallbladder stones (21.21%), 3 in 21 patients with inflammation and stricture of the end of the bile duct and papilla (14.29%), 1 in 22 patients with carcinoma of the end of the bile duct and papilla (4.54%), and 5 in 13 patients with post-cholecystectomy syndrome or sphincter of Oddi dysfunction (38.46%).
  • CONCLUSIONS: The incidence rate of intraduodenal peri-ampullary diverticulum in patients with primary bile duct pigment stones is higher than that in patients with bile duct stones secondary to gallbladder stones, patients with inflammation and stricture of the end of the bile duct and papilla, and patients with carcinoma of the end of the bile duct and papilla.

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548255.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Chiche L, Alkofer B, Parienti JJ, Rouleau V, Salamé E, Samama G, Segol P: Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater. HPB (Oxford); 2007;9(2):140-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater.
  • BACKGROUND: The prognosis for carcinoma of the ampulla of Vater (CAV) is better than for pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] HPB Surg. 1998;11(1):1-11 [9830575.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1973-9 [10430380.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2429-33 [10522012.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3274-5 [10626200.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):247-8 [11941966.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1116-9 [12143216.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1275-7 [15362731.001]
  • [Cites] Surgery. 2004 Nov;136(5):994-1002 [15523392.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784 [15531230.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1811-8 [15774774.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1717-20 [2208026.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):632-7 [7487210.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):102-6; discussion 106-7 [7740792.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):545-52 [7952456.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Eur J Surg. 1993 Feb;159(2):95-100 [8098633.001]
  • [Cites] Surg Gynecol Obstet. 1993 Oct;177(4):366-70 [8211580.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Eur J Surg. 1996 Jun;162(6):477-81 [8817225.001]
  • [Cites] Gut. 1997 Mar;40(3):350-5 [9135524.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Surgery. 1997 Jun;121(6):611-7 [9186460.001]
  • [Cites] Ann R Coll Surg Engl. 1997 Jul;79(4):259-63 [9244068.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1399-401 [9361598.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):600-3; discussion 603-4 [9409581.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Korean Med Sci. 1999 Apr;14(2):220-2 [10331573.001]
  • (PMID = 18333130.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020781
  •  go-up   go-down


33. Hsu HP, Shan YS, Hsieh YH, Yang TM, Lin PW: Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence. J Formos Med Assoc; 2007 Jun;106(6):432-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence.
  • BACKGROUND/PURPOSE: Ampullary cancer is one of the periampullary cancers with a better prognosis, but relapse still occurs early in some patients.
  • METHODS: Between January 1989 and March 2006, information was gathered on a total of 127 patients undergoing pancreaticoduodenectomy with regional lymphadenectomy for ampullary cancer at National Cheng Kung University Hospital and Tainan Municipal Hospital.
  • The early and late recurrence patients had higher levels of microscopically (R1) or macroscopically (R2) positive margin of resection and more advanced disease (advanced tumor stage, numbers of lymph nodes involved, lymph node status, pancreatic invasion and TNM stage) than the non-recurrence group.
  • After multivariate analysis, positive resection margin, pancreatic invasion and lymph node involvement were significant predictors for disease recurrence.
  • CONCLUSION: Positive resection margin, pancreatic invasion, and lymph node involvement were found to be predictors for disease recurrence and indicators for postoperative treatment.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588836.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


34. Nikfarjam M, Gusani NJ, Kimchi ET, Mahraj RP, Staveley-O'Carroll KF: Combined right nephrectomy and pancreaticoduodenectomy. Indications and outcomes. JOP; 2008;9(4):449-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Three patients had retroperitoneal sarcomas adherent to the right kidney and duodenum, one patient had a locally advanced transitional-cell carcinoma and the remaining patient presented with an ampullary malignancy and concurrent right renal tumor All patients underwent en bloc resection with clear margins.
  • CONCLUSION: En bloc right nephrectomy combined with pancreaticoduodenal resection can be performed in selected patients with malignant tumors with acceptable morbidity to achieve clear resection margins.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / statistics & numerical data. Outcome Assessment (Health Care). Pancreaticoduodenectomy / statistics & numerical data. Retroperitoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648136.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


35. Huang SS, Jan YJ, Cheng SB, Yeh DC, Wu CC, Liu TJ, P'eng FK: Large cell neuroendocrine carcinoma of the ampulla of vater: Report of a case. Surg Today; 2006;36(11):1032-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the ampulla of vater: Report of a case.
  • Large cell neuroendocrine carcinoma in the ampulla of Vater is rare and very different from the common ampullary adenocarcinoma.
  • Gastroendoscopy showed a swollen ampulla of Vater and pathological examination of an ampullary biopsy revealed findings of a carcinoid tumor.
  • A diagnosis of large cell neuroendocrine carcinoma was confirmed by immunohistochemical examination of the resected specimen.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Endoscopy, Gastrointestinal. Fatal Outcome. Humans. Male. Middle Aged. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1424-8 [11023106.001]
  • [Cites] Head Neck. 1991 Nov-Dec;13(6):498-508 [1665150.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1580-8 [8156484.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):1016-20 [9796733.001]
  • [Cites] Surg Today. 2003;33(11):870-2 [14605962.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1108-12 [11571722.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] Surgery. 1994 Jun;115(6):762-6 [8197570.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):187-91 [11426984.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • [Cites] Arch Surg. 2005 Jun;140(6):529-32; discussion 532-3 [15967899.001]
  • [Cites] Eur J Surg Oncol. 1990 Jun;16(3):183-8 [2347413.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1098-100 [15452169.001]
  • [Cites] J Clin Pathol. 2001 Nov;54(11):880-2 [11684726.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):221-3 [12562240.001]
  • [Cites] Surg Today. 2005;35(5):345-50 [15864414.001]
  • [Cites] Surgery. 1999 Mar;125(3):250-6 [10076608.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):838-41 [15557973.001]
  • (PMID = 17072731.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Sakata E, Shirai Y, Yokoyama N, Wakai T, Sakata J, Hatakeyama K: Clinical significance of lymph node micrometastasis in ampullary carcinoma. World J Surg; 2006 Jun;30(6):985-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of lymph node micrometastasis in ampullary carcinoma.
  • BACKGROUND: This study aimed to clarify the clinical significance of lymph node micrometastasis in ampullary carcinoma.
  • MATERIALS AND METHODS: Pancreaticoduodenectomy with regional lymphadenectomy was performed for 50 consecutive patients with ampullary carcinoma.
  • CONCLUSIONS: Immunohistochemically detected lymph node micrometastasis indicates intensive lymphatic spread, and thus adversely affects the survival of patients with ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Keratins / analysis. Lymph Node Excision. Lymph Nodes / chemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1984 Aug;50(2):193-7 [6380553.001]
  • [Cites] Surgery. 1996 Apr;119(4):397-402 [8644003.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):201-7 [12560778.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):769-78 [10091753.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Nov;122(5):900-6 [11689794.001]
  • [Cites] J Surg Oncol. 1996 Mar;61(3):190-4 [8637205.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3853-6 [8033106.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1465-9 [10193935.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1717-20 [2208026.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):88-95 [8554990.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):858-66 [9731887.001]
  • [Cites] Histopathology. 1998 Mar;32(3):199-208 [9568504.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2105-13 [14601079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):1012-6 [9240155.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1244-9 [9788387.001]
  • [Cites] Am J Surg. 1989 Dec;158(6):593-6; discussion 596-7 [2589595.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1069-76 [9070482.001]
  • [Cites] Surgery. 2001 Jun;129(6):704-13 [11391369.001]
  • [Cites] Aust N Z J Surg. 1993 Apr;63(4):256-62 [7906119.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):133-9 [11753052.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1595-600 [7520351.001]
  • [Cites] Surgery. 2000 Jan;127(1):32-9 [10660756.001]
  • (PMID = 16736326.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


37. Alsaif F: Pylorus preserving pancreaticoduodenectomy for peri-ampullary carcinoma, is it a good option? Saudi J Gastroenterol; 2010 Apr-Jun;16(2):75-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pylorus preserving pancreaticoduodenectomy for peri-ampullary carcinoma, is it a good option?
  • Pancreaticoduodenectomy (PD) is the standard surgical treatment for resectable peri-ampullary tumors.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Pylorus
  • [MeSH-minor] Ampulla of Vater / pathology. Ampulla of Vater / surgery. Anastomosis, Surgical / adverse effects. Anastomosis, Surgical / methods. Blood Loss, Surgical. Blood Transfusion. Female. Follow-Up Studies. Gastric Emptying / physiology. Hospital Mortality / trends. Humans. Intraoperative Complications / mortality. Length of Stay. Male. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Postoperative Complications / mortality. Postoperative Complications / prevention & control. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Jan;24(1):66-70; discussion 70-1 [10594206.001]
  • [Cites] Surg Gynecol Obstet. 1946 Jun;82:623-31 [20983134.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):193-7 [10982613.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1236-41; discussion 1242 [11071469.001]
  • [Cites] Dig Dis Sci. 2000 Oct;45(10):1907-12 [11117559.001]
  • [Cites] J Gastroenterol. 2002;37(8):596-603 [12203074.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):859-65 [12788421.001]
  • [Cites] Surgery. 2003 Jun;133(6):647-55 [12796733.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):758-65 [13129553.001]
  • [Cites] Am J Surg. 2004 Jun;187(6):743-6 [15191869.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] Ann Surg. 1980 Sep;192(3):306-10 [7416828.001]
  • [Cites] Surgery. 1989 May;105(5):645-53 [2650006.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] J Am Coll Surg. 1997 Oct;185(4):373-9 [9328386.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):467-70 [9874435.001]
  • [Cites] World J Surg. 1999 Sep;23(9):920-5 [10449821.001]
  • [Cites] Langenbecks Arch Surg. 1999 Aug;384(4):354-9 [10473855.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):303-11 [10526067.001]
  • [Cites] Ann Surg Oncol. 2005 Mar;12(3):222-7 [15827814.001]
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):328-31 [15905037.001]
  • [Cites] World J Surg. 2005 Jul;29(7):873-9; discussion 880 [15951944.001]
  • [Cites] World J Surg. 2005 Jul;29(7):881-4 [15951940.001]
  • [Cites] World J Surg. 2005 Oct;29(10):1319-24 [16284796.001]
  • [Cites] Langenbecks Arch Surg. 2006 Jun;391(3):195-202 [16491403.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1825-34 [17342566.001]
  • [Cites] World J Surg. 2007 Aug;31(8):1606-15 [17566824.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(3):262-9 [18535763.001]
  • [Cites] J Med Assoc Thai. 2008 May;91(5):693-8 [18672634.001]
  • [Cites] Eur J Surg Oncol. 2008 Nov;34(11):1237-45 [18242943.001]
  • [CommentIn] Saudi J Gastroenterol. 2010 Apr-Jun;16(2):65 [20339172.001]
  • (PMID = 20339174.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 36
  • [Other-IDs] NLM/ PMC3016509
  •  go-up   go-down


38. Artifon EL, Couto D Jr, Sakai P, da Silveira EB: Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc; 2009 Aug;70(2):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of EUS versus CT scan for staging of ampullary cancer.
  • BACKGROUND: Malignancies of the biliary and pancreatic systems are associated with a poor prognosis.
  • However, ampullary cancer carries a better prognosis and is often diagnosed when curative treatment is still possible.
  • (1) To determine the test performance characteristics of EUS and CT in loco-regional staging of ampullary neoplasms, and (2) to determine the impact of CT scan results on the test performance characteristics of EUS.
  • Further studies to determine the role of specialized CT protocols in patients with ampullary malignancies are needed.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology. Endosonography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523619.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Small AJ, Baron TH: Successful endoscopic resection of ampullary adenoma with intraductal extension and invasive carcinoma (with video). Gastrointest Endosc; 2006 Jul;64(1):148-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful endoscopic resection of ampullary adenoma with intraductal extension and invasive carcinoma (with video).
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Ampulla of Vater. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16813830.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Tonini G, Virzì V, Fratto ME, Vincenzi B, Santini D: Targeted therapy in biliary tract cancer: 2009 update. Future Oncol; 2009 Dec;5(10):1675-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy in biliary tract cancer: 2009 update.
  • Biliary tract cancers (BTCs) include cholangiocarcinoma (intrahepatic, perihilar and extrahepatic), carcinoma of the gall bladder and ampullary carcinoma.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001803.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 78
  •  go-up   go-down


41. Yang YM, Tian XD, Zhuang Y, Wang WM, Wan YL, Huang YT: Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol; 2005 Apr 28;11(16):2456-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors of pancreatic leakage after pancreaticoduodenectomy.
  • AIM: To analyze the risk factors for pancreatic leakage after pancreaticoduodenectomy (PD) and to evaluate whether duct-to-mucosa pancreaticojejunostomy could reduce the risk of pancreatic leakage.
  • The primary diseases of the patients included pancreas cancer, ampullary cancer, bile duct cancer, islet cell cancer, duodenal cancer, chronic pancreatitis, pancreatic cystadenoma, and gastric cancer.
  • A duct-to-mucosa pancreaticojejunostomy was performed for patients with a hard pancreas and a dilated pancreatic duct, and a traditional end-to-end invagination pancreaticojejunostomy for patients with a soft pancreas and a non-dilated duct.
  • Seven preoperative and six intraoperative risk factors with the potential to affect the incidence of pancreatic leakage were analyzed with SPSS10.0 software.
  • Logistic regression was then used to determine the effect of multiple factors on pancreatic leakage.
  • RESULTS: Of the 62 patients, 10 (16.13%) were identified as having pancreatic leakage after operation.
  • The hospital mortality in this series was 4.84% (3/62), and the mortality associated with pancreatic fistula was 10% (1/10).
  • Sixteen cases underwent duct-to-mucosa pancreaticojejunostomy and 1 case (1/16, 6.25%) developed postoperative pancreatic leakage, 46 cases underwent invagination pancreaticojejunostomy and 9 cases (9/46, 19.6%) developed postoperative pancreatic leakage.
  • General risk factors including patient age, gender, history of jaundice, preoperative nutrition, pathological diagnosis and the length of postoperative stay were similar in the two groups.
  • There was no statistical difference in the incidence of pancreatic leakage between the patients who received the prophylactic use of octreotide after surgery and the patients who did not undergo somatostatin therapy.
  • Moreover, multivariate logistic regression analysis showed that none of the above factors seemed to be associated with pancreatic fistula.
  • Two intraoperative risk factors, pancreatic duct size and texture of the remnant pancreas, were found to be significantly associated with pancreatic leakage.
  • The incidence of pancreatic leakage was 4.88% in patients with a pancreatic duct size greater than or equal to 3 mm and was 38.1% in those with ducts smaller than 3 mm (P = 0.002).
  • The pancreatic leakage rate was 2.94% in patients with a hard pancreas and was 32.1% in those with a soft pancreas (P = 0.004).
  • The incidence of pancreatic leakage was 6.25% (1/16) in patients with duct-to-mucosa anastomosis, and was 19.6% (9/46) in those with traditional invagination anastomosis.
  • Although the difference of pancreatic leakage between the two groups was obvious, no statistical significance was found.
  • By further analyzing with multivariate logistic regression, both pancreatic duct size and texture of the remnant pancreas were demonstrated to be independent risk factors (P = 0.007 and 0.017, OR = 11.87 and 15.45).
  • Although anastomotic technique was not a significant factor, pancreatic leakage rate was much less in cases that underwent duct-to-mucosa pancreaticojejunostomy.
  • CONCLUSION: Pancreatic duct size and texture of the remnant pancreas are risk factors influencing pancreatic leakage after PD.
  • Duct-to-mucosa pancreaticojejunostomy, as a safe and useful anastomotic technique, can reduce pancreatic leakage rate after PD.
  • [MeSH-major] Intraoperative Complications / epidemiology. Pancreatic Diseases / epidemiology. Pancreatic Diseases / surgery. Pancreaticoduodenectomy / adverse effects. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Aged. Duodenum / surgery. Female. Humans. Male. Middle Aged. Pancreas / surgery. Pancreatic Ducts / surgery. Risk Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305634
  •  go-up   go-down


42. Fujita T, Konishi M, Gotohda N, Takahashi S, Nakagohri T, Kojima M, Kinoshita T: Invasive micropapillary carcinoma of the ampulla of Vater with extensive lymph node metastasis: Report of a case. Surg Today; 2010 Dec;40(12):1197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the ampulla of Vater with extensive lymph node metastasis: Report of a case.
  • Invasive micropapillary carcinoma is characterized by extensive lymph node metastasis and a poor prognosis.
  • This histological variant was first described in breast cancer, with a few subsequent reports of it in the ampullo-pancreato-biliary region.
  • We report a case of invasive micropapillary carcinoma of the papilla of Vater.
  • Detailed investigations revealed a tumor in the periampullary region, and pancreatoduodenectomy was performed for cancer of the ampulla of Vater.
  • Microscopic examination of the resected specimen revealed a tumor composed mainly of carcinoma cells arranged in micropapillary structures, with extensive regional lymph node metastasis.
  • [MeSH-major] Ampulla of Vater / pathology. Ampulla of Vater / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Fatal Outcome. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Nov;18(11):1504-11 [16007065.001]
  • [Cites] Histopathology. 2005 Nov;47(5):479-84 [16241995.001]
  • [Cites] Pancreas. 2007 Aug;35(2):190-2 [17632330.001]
  • [Cites] J Urol. 1999 Jun;161(6):1798-802 [10332438.001]
  • [Cites] Mod Pathol. 1993 Nov;6(6):660-2 [8302807.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):836-41 [11557778.001]
  • [Cites] BMC Urol. 2009 Jun 17;9:5 [19534791.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):583-9 [11431712.001]
  • [Cites] Histopathology. 2009 May;54(6):741-50 [19438749.001]
  • [Cites] Histol Histopathol. 2005 Jul;20(3):791-9 [15944928.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1459-63 [10667424.001]
  • [Cites] Histopathology. 2005 Jan;46(1):24-30 [15656882.001]
  • (PMID = 21110170.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Kim S, Lee NK, Lee JW, Kim CW, Lee SH, Kim GH, Kang DH: CT evaluation of the bulging papilla with endoscopic correlation. Radiographics; 2007 Jul-Aug;27(4):1023-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT evaluation of the bulging papilla with endoscopic correlation.
  • A variety of pathologic conditions can cause abnormalities of the ampulla of Vater.
  • A bulging papilla is frequently encountered at computed tomography (CT) and can be seen in healthy individuals as well as in patients with various pathologic conditions such as papillitis, ampullary cancer, and intraductal papillary mucinous tumor.
  • Mural thickening and certain attenuation patterns seen at contrast material-enhanced CT can help differentiate pathologic papilla from normal papilla.
  • Increased targetlike enhancement of the papilla is likely to represent a benign condition such as papillitis, whereas an enhancing polypoid mass or focal asymmetric or irregular thickening with prolonged enhancement in the ampulla of Vater indicates a malignant condition such as ampullary or periampullary carcinoma.
  • Although CT often does not clarify the exact cause of bulging, adequate duodenal distention may allow detection of an abnormal papilla, thereby providing additional information about other abnormalities in the pancreaticobiliary system.
  • MR cholangiography may be equivalent to CT for identifying a bulging papilla and superior for distinguishing the underlying cause.
  • However, endoscopy with or without biopsy is the best method for making a definitive diagnosis in patients with a bulging papilla.
  • Familiarity with the normal imaging anatomy of the periampullary region and with the imaging features of the various pathologic causes of a bulging papilla may be useful in making the diagnosis.
  • [MeSH-major] Bile Duct Diseases / diagnosis. Bile Ducts / pathology. Cholangiography / methods. Endoscopy / methods. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Middle Aged. Practice Guidelines as Topic. Practice Patterns, Physicians'. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2007
  • (PMID = 17620465.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


44. Kamisawa T, Tu Y, Egawa N, Tsuruta K, Okamoto A, Funata N: Endocrine cells in ampullary carcinoma. J Hepatobiliary Pancreat Surg; 2009;16(3):322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine cells in ampullary carcinoma.
  • BACKGROUND/PURPOSE: As ampullary carcinoma originates from four anatomical regions, it may have different behaviors depending on its origin.
  • We documented the presence of endocrine cells found in ampullary carcinoma, and we studied the clinicopathological implications of their presence.
  • METHODS: We immunohistochemically examined the presence of an endocrine component in 62 surgically resected specimens of ampullary carcinoma, and we studied the clinicopathological differences between endocrine component-positive cases and endocrine component-negative cases.
  • The histology of 15 of the 16 endocrine component-positive ampullary carcinomas was the intestinal type.
  • Pancreatic invasion and lymph node involvement were observed less frequently in endocrine component-positive cases (P < 0.01).
  • CONCLUSIONS: Endocrine component-positive ampullary carcinoma seemed to be derived from the ampullopancreaticobiliary common duct or the ampulloduodenum, and to behave less aggressively than endocrine component-negative carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Endocrine Cells / pathology. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19214369.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


45. Brown KM, Tompkins AJ, Yong S, Aranha GV, Shoup M: Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg; 2005 Jun;140(6):529-32; discussion 532-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer.
  • HYPOTHESIS: Survival following resection for ampullary carcinoma may be influenced by 1 or more clinical or pathologic variables.
  • PATIENTS: From July 1, 1991, through April 30, 2004, 72 patients (31 males and 41 females) were treated for ampullary carcinoma at Loyola University Medical Center, Maywood, Ill.
  • INTERVENTIONS: Whipple procedure for attempted cure in 51 patients with ampullary adenocarcinoma.
  • CONCLUSION: Pancreaticoduodenectomy is curative in 80% of patients with node-negative ampullary carcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater. Blood Loss, Surgical. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2005 Jul;140(7):708 [16027340.001]
  • (PMID = 15967899.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Schirmacher P, Büchler MW: Ampullary adenocarcinoma - differentiation matters. BMC Cancer; 2008;8:251
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary adenocarcinoma - differentiation matters.
  • This fuels the discussion about maintaining ampullary cancer as a separate entity.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Differentiation. Diagnosis, Differential. Epithelium / pathology. Humans. Medical Oncology / methods. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2422-32 [11331321.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Eur J Surg Oncol. 2009 Feb;35(2):187-91 [18343082.001]
  • [Cites] Surgery. 2006 Nov;140(5):764-72 [17084719.001]
  • [Cites] BMC Cancer. 2008;8:170 [18547417.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • (PMID = 18761739.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2553420
  •  go-up   go-down


47. Perrone G, Santini D, Zagami M, Vincenzi B, Verzì A, Morini S, Borzomati D, Coppola R, Antinori A, Magistrelli P, Tonini G, Rabitti C: COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. Virchows Arch; 2006 Sep;449(3):334-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters.
  • Epidemiological studies suggest that regular intake of nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with reduced incidence of gastrointestinal cancer.
  • The aim of our study was to assess COX-2 expression in a series of primary untreated ampullary carcinomas and its possible correlation with clinicopathological parameters.
  • In the present study, 45 surgical specimens of invasive ampullary carcinomas were histologically classified into pancreaticobiliary, intestinal, and unusual types.
  • High COX-2 expression was detected in 35 (77.8%) ampullary carcinomas.
  • The different COX-2 expression among histopathological types supports the concept of histogenetical difference of ampullary carcinomas.
  • Furthermore, the high rate of COX-2 expression in the intestinal subtype of ampullary carcinoma may represent the rational for a histotype-tailored therapy targeting COX-2.
  • [MeSH-major] Adenocarcinoma / enzymology. Ampulla of Vater / enzymology. Common Bile Duct Neoplasms / enzymology. Cyclooxygenase 2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Histopathology. 2005 May;46(5):561-8 [15842638.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4574-7 [10493510.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11 [15179620.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1445-61 [15887126.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):139-46 [11266517.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Circulation. 1998 Jan 6-13;97(1):99-107 [9443437.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3784-9 [15897577.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hepatology. 2001 Apr;33(4):860-7 [11283850.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):218-24 [12692419.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4424-9 [8813136.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):544-51 [11905709.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):361-70 [10605031.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2128-34 [10445539.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 6;83(5):355-8 [1759994.001]
  • [Cites] J Clin Pathol. 2006 May;59(5):492-6 [16489179.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1339-47 [11729113.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2018-24 [10473081.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):4997-5001 [9823297.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):30-6 [15252927.001]
  • [Cites] Epidemiology. 1996 Mar;7(2):203-5 [8834563.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):362-6 [9443418.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):596-607 [10440687.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):403-5 [10821484.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1394-402 [3422832.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):198-204 [9892207.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1586-91 [12496048.001]
  • [Cites] Br J Pharmacol. 2002 May;136(2):287-95 [12010778.001]
  • (PMID = 16906389.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


48. Park S, Kim SW, Lee BL, Jung EJ, Kim WH: Expression of E-cadherin and beta-catenin in the adenoma-carcinoma sequence of ampulla of Vater cancer. Hepatogastroenterology; 2006 Jan-Feb;53(67):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of E-cadherin and beta-catenin in the adenoma-carcinoma sequence of ampulla of Vater cancer.
  • BACKGROUND/AIMS: Ampullary carcinoma is uncommon but provides a good model for adenoma-carcinoma sequence.
  • During the adenoma-carcinoma transition, the tumor cells should acquire the ability to invade.
  • METHODOLOGY: 111 cases of ampullary carcinoma were investigated with E-cadherin and beta-catenin expression with immunohistochemistry and the result was compared with their clinicopathologic and survival results.
  • RESULTS: Expressional loss of E-cadherin was detected in 3 (6.1%) adenomas and 73 (65.8%) carcinomas, and the expressional loss was significantly associated with tumor cell differentiation (p<0.05) and survival (p<0.05) in carcinoma.
  • CONCLUSIONS: Alteration of E-cadherin and beta-catenin is a late event during the adenoma-carcinoma sequence in ampullary neoplasms, and the loss of membranous expression of both E-cadherin and beta-catenin is closely correlated with less differentiated histology and poor prognosis.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Ampulla of Vater. Cadherins / biosynthesis. Carcinoma / metabolism. Carcinoma / pathology. Common Bile Duct Neoplasms / metabolism. Common Bile Duct Neoplasms / pathology. beta Catenin / biosynthesis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506371.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


49. De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, Wolfgang CL, Herman JM, Edil BH, Choti MA, Schulick RD, Nagorney DM, Pawlik TM: Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg; 2010 Jul;252(1):142-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Primary tumor histology included neuroendocrine carcinoma (34.9%), pancreatic ductal adenocarcinoma (33.4%), distal cholangiocarcinoma (8.7%), ampullary carcinoma (7.1%), duodenal carcinoma (4.0%), or other (11.9%).
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma / pathology. Carcinoma, Ductal / pathology. Carcinoma, Neuroendocrine / pathology. Cholangiocarcinoma / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531007.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


50. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ 3rd, Moser AJ: Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg; 2008 Oct;12(10):1664-72; discussion 1672-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
  • BACKGROUND: American Joint Committee on Cancer (AJCC) staging for pancreatic adenocarcinoma is a validated predictor of prognosis but insufficiently discriminates postresection survival.
  • METHODS: Resected pancreatic ductal and ampullary adenocarcinomas (n = 50) were analyzed for loss of heterozygosity (LOH) at 15 markers including 5q(APC), 6q(TBSP2), 9p(p16), 10q(PTEN), 12q(MDM2), 17p(TP53), and 18q(DCC/SMAD4).
  • CONCLUSION: LOH and KRAS mutations indicate aggressive tumor biology and correlate strongly with survival in resected pancreatic ductal and ampullary carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Ampulla of Vater. Common Bile Duct Neoplasms / genetics. Loss of Heterozygosity. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / surgery. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Mutation. Pancreatectomy. Pilot Projects. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins p21(ras). Retrospective Studies. Survival Analysis. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] Pancreas. 1996 May;12(4):373-80 [8740405.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7529-35 [16234519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14888-93 [10611308.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2080-5 [10950061.001]
  • [Cites] Development. 2007 Aug;134(15):2719-25 [17596282.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):15-29 [10721693.001]
  • [Cites] World J Gastroenterol. 2005 Apr 14;11(14 ):2162-5 [15810085.001]
  • [Cites] Breast Cancer Res. 2006;8(3):R25 [16737553.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:601-32 [1667084.001]
  • [Cites] Science. 1998 May 15;280(5366):1036-7 [9616081.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4670-5 [7553647.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):871-5 [14871814.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jun;103(2):197-208 [17039265.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):488-99 [11505392.001]
  • [Cites] Oncogene. 2007 Jul 19;26(33):4850-62 [17297450.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784 [15531230.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Liver Transpl. 2003 Jul;9(7):664-71 [12827550.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):738-44 [17580363.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):235-41 [16397047.001]
  • [Cites] Science. 1987 Jun 26;236(4809):1657-61 [2885916.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):326-32 [10023699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10 ):3933-8 [18316739.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):85-94 [11511362.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):383-91 [9408755.001]
  • [Cites] Ann Intern Med. 2008 Mar 4;148(5):358-69 [18252678.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):5044-52 [14581380.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Mol Cancer. 2003 Jan 07;2:7 [12537585.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):545-52 [18199551.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):173-80 [17667493.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):293-8 [15273554.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):147-53 [8597508.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):75-83; discussion 83 [18209156.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):701-6 [18027062.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):347-56 [16504879.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):262-7 [9561851.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):607-13 [12642681.001]
  • [Cites] Ann Surg Oncol. 2006 Sep;13(9):1189-200 [16955385.001]
  • [Cites] Blood. 1995 Aug 1;86(3):841-54 [7620180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9624-9 [10944227.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Surgery. 2007 May;141(5):610-8 [17462460.001]
  • (PMID = 18677542.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


51. Carter RR, Woodall CE 3rd, McNally ME, Talboy GE, Lankachandra KM, Van Way CW 3rd: Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors. Am Surg; 2008 Apr;74(4):338-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors.
  • This report is a case of a 58-year-old woman with a mixed ductal-endocrine carcinoma of the pancreas and a synchronous carcinoma-in-situ of the common bile duct.
  • Endoscopic retrograde cholangiopancreatography revealed an ulcerated lesion of the ampulla.
  • Subsequently, pancreatoduodenectomy was performed for the diagnosis of peri-ampullary carcinoma.
  • On histopathological examination, it was discovered that this lesion contained two separate neoplasms: papillary carcinoma-in-situ of the intraparenchymal portion of the common bile duct and a mixed ductal-endocrine carcinoma of the pancreas.
  • Mixed ductal-endocrine carcinoma of the pancreas is very rare.
  • Finding it in conjunction with a synchronous, overlying papillary carcinoma carcinoma-in-situ of the common bile duct has not been previously described.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Common Bile Duct Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology


52. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med; 2010 Apr 8;362(14):1273-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
  • BACKGROUND: There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer.
  • METHODS: We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks.
  • Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769. )

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [CommentIn] Z Gastroenterol. 2010 Aug;48(8):850-1 [20687022.001]
  • [CommentIn] N Engl J Med. 2010 Apr 8;362(14):1335-7 [20375411.001]
  • [CommentIn] J Hepatol. 2011 Mar;54(3):577-8 [21112109.001]
  • [CommentIn] N Engl J Med. 2010 Jul 8;363(2):192; author reply 192-3 [20653076.001]
  • [CommentIn] N Engl J Med. 2010 Jul 8;363(2):192; author reply 192-3 [20647216.001]
  • [CommentIn] Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):395-7 [20678012.001]
  • (PMID = 20375404.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00262769
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Investigator] Nicholson M; Corrie P; Eatock M; Falk S; Elyan S; Valle J; Anthony A; Nicoll J; Kulkarni R; Osbourne R; Garcia Alonso A; Wasan H; Waters J; Harrison M; Adamson D; Rees C; Bridgewater J; Madhusudan S; McAdam K; Bridgewater J; Maraveyas A; Palmer D; Hickish T; Meyer T; Cunningham D; Iveson T; Middleton G; Slater S; Lofts F; Archer C; Iveson T; Iveson T; Bridgewater J; Mukherjee S; Wadsley J; Gollins S
  •  go-up   go-down


53. Peng SY, Hong DF, Liu YB, Tan ZJ, Li JT, Tao F: [Binding pancreaticogastrostomy]. Zhonghua Wai Ke Za Zhi; 2009 Jan 15;47(2):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From May 2008 to October 2008, 15 patients were performed with BPG, included pancreatic head cancer in 7 cases, duodenal adenocarcinoma in 2 cases,mass-type chronic pancreatitis with pancreatolithiasis in 1 case, ampullary carcinoma in 1 case, gallbladder cancer in 1 case, islet cell tumor in 1 case and cholangiocarcinoma in 2 cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563012.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


54. Rossaak J, Bagshaw P, Connor S: Management of Duodenal Adenomas Involving the Ampulla of Vater - A Warning against Limited Resection. Case Rep Gastroenterol; 2008;2(1):96-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Duodenal Adenomas Involving the Ampulla of Vater - A Warning against Limited Resection.
  • This case report describes two patients with adenomas involving the ampulla of Vater.
  • Histology of both specimens demonstrated that the adenoma had migrated up the bile duct for at least 7 mm, and the pancreatic duct for 8 mm in one patient.
  • Limited resection of ampullary adenomas may leave residual adenomatous tissue in the bile duct with the risk of recurrent adenomatous disease and malignant transformation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Yonsei Med J. 2000 Apr;41(2):213-8 [10817022.001]
  • [Cites] Arch Surg. 2002 May;137(5):557-62; discussion 562-3 [11982469.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):831-7; discussion 837 [12504221.001]
  • [Cites] Ulster Med J. 2002 Nov;71(2):121-7 [12513008.001]
  • [Cites] ANZ J Surg. 2007 May;77(5):371-3 [17497979.001]
  • [Cites] Scand J Gastroenterol. 1994 Jun;29(6):483-7 [8079103.001]
  • [Cites] Br J Surg. 1998 May;85(5):665-8 [9635818.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):493-8 [14752072.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):245-51 [15368108.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):559-64 [15239991.001]
  • (PMID = 21490846.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3075174
  • [Keywords] NOTNLM ; Ampullary adenoma/carcinoma / Duodenal adenoma/carcinoma / High-grade dysplasia / Management / Surgery
  •  go-up   go-down


55. Gandini R, Fabiano S, Pipitone V, Spinelli A, Reale CA, Colangelo V, Pampana E, Romagnoli A, Simonetti G: Management of biliary neoplastic obstruction with two different metallic stents implanted in one session. Cardiovasc Intervent Radiol; 2005 Jan-Feb;28(1):48-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of the "one-step" technique using two different metallic stents (Wallstent and Ultraflex) and associated rate of complications was studied in 87 patients with jaundice secondary to malignant biliary obstruction, with bilirubin level less than 15 mg/dl and Bismuth type 1 or 2 strictures.
  • The cause of the obstruction was pancreatic carcinoma in 38 patients (44%), lymph node metastasis in 20 patients (23%), gallbladder carcinoma in 13 patients (15%), cholangiocarcinoma in 12 patients (14%) and ampullary carcinoma in four patients (5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772722.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Imazu H, Uchiyama Y, Matsunaga K, Ikeda K, Kakutani H, Sasaki Y, Sumiyama K, Ang TL, Omar S, Tajiri H: Contrast-enhanced harmonic EUS with novel ultrasonographic contrast (Sonazoid) in the preoperative T-staging for pancreaticobiliary malignancies. Scand J Gastroenterol; 2010 Jun;45(6):732-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final diagnosis were pancreatic cancer in 11, bile duct cancer in 7, gallbladder cancer in 4 and ampullary cancer in 4.
  • CH-EUS staged correctly in all of these six cases, whereas H-EUS misdiagnosed the depth of invasion in one case of gallbladder cancer and one case of ampullary cancer, and invasion of portal vein in two cases of pancreatic cancer and two cases of bile duct cancer.
  • CONCLUSION: The depth of invasion of biliary cancer and vascular invasion of pancreatic and biliary cancer could be demonstrated more clearly with CH-EUS compared to H-EUS.
  • [MeSH-major] Biliary Tract Neoplasms / ultrasonography. Contrast Media / administration & dosage. Endosonography / methods. Ferric Compounds. Iron. Neoplasm Staging / methods. Oxides. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Injections, Intravenous. Pilot Projects. Preoperative Period. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205504.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 0 / Oxides; 0 / Sonazoid; E1UOL152H7 / Iron
  •  go-up   go-down


57. DeWitt J, Alsatie M, LeBlanc J, McHenry L, Sherman S: Endoscopic ultrasound-guided fine-needle aspiration of left adrenal gland masses. Endoscopy; 2007 Jan;39(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Our searches resulted in the identification of a series of 38 consecutive patients who underwent EUS for the evaluation of a lung mass (n = 14), a pancreatic mass (n = 14), obstructive jaundice (n = 1), dysphagia (n = 2), an ampullary adenoma (n = 1), celiac block (n = 1), or a left adrenal gland mass (n = 5).
  • Diagnoses after EUS-FNA (the mean number of passes was 3.6) were: metastatic lung cancer (n = 2), esophageal adenocarcinoma (n = 1), melanoma (n = 1), renal cell carcinoma (n = 1), and pancreatic neuroendocrine tumor (n = 1); primary pheochromocytoma (n = 1); benign adrenal tissue (n = 21); and granulomatous inflammation (n = 1).


58. Wasan SM, Ross WA, Staerkel GA, Lee JH: Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol; 2005 Sep;100(9):2056-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of expandable metallic biliary stents in resectable pancreatic cancer.
  • AIM: To compare the efficacy of metal versus plastic stents for biliary strictures in patients with surgically resectable pancreatic cancer.
  • Of the 12 patients with pancreaticoduodenectomy, 10 had pancreatic adenocarcinoma, 1 intraductal papillary mucinous tumor, and 1 ampullary cancer.
  • Of the 35 patients, 27 had pancreatic adenocarcinoma, 5 ampullary cancer, 1 neuroendocrine tumor, 1 microcystic adenoma, and 1 autoimmune pancreatitis.
  • CONCLUSIONS: Contrary to the belief that metal stents are contraindicated for patients with surgically resectable pancreatic cancer, our study demonstrated that metal stents provided a longer patency rate, fewer ERCP sessions, and fewer episodes of cholangitis without adding any intra- or postoperative complications.
  • Therefore, metal stents should be considered for patients with resectable pancreatic cancer, especially if surgery is not immediately planned as more patients are now receiving preoperative chemoradiation.
  • [MeSH-major] Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / therapy. Stents

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128952.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metals; 0 / Plastics
  •  go-up   go-down


59. Swain JM, Adams RB, Farnell MB, Que FG, Sarr MG: Gastric and pancreatoduodenal resection for malignant lesions after previous gastric bypass--diagnosis and methods of reconstruction. Surg Obes Relat Dis; 2010 Nov-Dec;6(6):670-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric and pancreatoduodenal resection for malignant lesions after previous gastric bypass--diagnosis and methods of reconstruction.
  • BACKGROUND: The diagnosis and treatment of gastric and pancreatoduodenal neoplasms after previous gastric bypass has been limited.
  • The diagnosis and resection of these neoplasms and restoration of biliopancreatic intestinal continuity pose challenges.
  • We present a 2-institutional experience of diagnosis and reconstruction after resection of gastric and pancreatoduodenal neoplasms and discuss the technical options for reconstruction.
  • METHODS: The medical records were reviewed retrospectively from 2003 to 2009 for patients with previous gastric bypass who developed a gastric or pancreatoduodenal neoplasm.
  • RESULTS: Of the available patients, 7 were identified with 2 remnant gastric cancers (2 signet ring cell adenocarcinomas), 4 pancreatic neoplasms (2 adenocarcinomas and 2 neuroendocrine cancers), and 1 ampullary cancer.
  • The pancreatic and duodenal neoplasms required pancreatoduodenectomy, with 4 of 5 patients also undergoing remnant gastrectomy.
  • The patients after pancreatoduodenectomy required biliary and pancreatic reconstruction with the pancreaticobiliary limb, Roux limb, or proximal common channel, depending on the limb length.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Duodenal Neoplasms / surgery. Gastrectomy / methods. Gastric Bypass. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / epidemiology. Adenoma, Islet Cell / surgery. Aged. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / epidemiology. Carcinoma, Neuroendocrine / surgery. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / epidemiology. Common Bile Duct Neoplasms / surgery. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20627707.001).
  • [ISSN] 1878-7533
  • [Journal-full-title] Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • [ISO-abbreviation] Surg Obes Relat Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Gooszen H: [Carcinoma of the head of the pancreas: indication for emergency surgery]. Ned Tijdschr Geneeskd; 2010;154:A2148
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the head of the pancreas: indication for emergency surgery].
  • In a recent multicentre randomized clinical trial, Van der Gaag et al. randomly assigned 220 patients to early surgery or preoperative biliary drainage ('Preoperative drainage for cancer of the head of the pancreas').
  • If forthcoming publications by this research group confirm this suggestion, the current paradigm - obstructive jaundice, endoscopic retrograde cholangiopancreatography with stenting, delayed surgery for carcinoma of the head of the pancreas - should be changed to: obstructive jaundice due to peri-ampullary carcinoma should be considered an indication for emergency surgery.
  • [MeSH-major] Carcinoma / surgery. Drainage / adverse effects. Pancreatic Neoplasms / surgery. Postoperative Complications / epidemiology. Preoperative Care

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ned Tijdschr Geneeskd. 2010;154(29):A1883 [20699038.001]
  • (PMID = 20699039.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Comment
  • [Publication-country] Netherlands
  •  go-up   go-down


61. Kala Z, Weber P, Hemmelová B, Marek F, Hlavsa J, Sobotka M: Ampullary tumours (ampullomas) in the elderly--an interdisciplinary problem. Indian J Med Res; 2010 Mar;131:418-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary tumours (ampullomas) in the elderly--an interdisciplinary problem.
  • BACKGROUND & OBJECTIVES: Ampullary cancer is one of the periampullary tumours with better prognosis, but relapses occur early in some patients.
  • METHODS: Between 2005 and 2007, 19 patients (12 male, 7 female) aged over 65 yr (range 66 and 83 yr) with diagnosis of ampulloma were operated.
  • RESULTS: Of the 19 patients, 6 underwent local surgical ampullectomy with reinsertion of ductus choledochus and Wirsungi's duct for benign or early cancer lesion and 13 underwent PDE (Whipple operation).
  • INTERPRETATION & CONCLUSIONS: Diagnosis and therapy of ampullary tumours is multimodal.
  • [MeSH-major] Ampulla of Vater / pathology. Ampulla of Vater / surgery. Common Bile Duct Diseases / diagnosis. Common Bile Duct Diseases / therapy. Common Bile Duct Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418556.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


62. Kawakami H, Zen Y, Kuwatani M, Eto K, Haba S, Yamato H, Shinada K, Kubota K, Asaka M: IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater's ampulla and the bile duct. J Gastroenterol Hepatol; 2010 Oct;25(10):1648-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater's ampulla and the bile duct.
  • The present study was carried out to examine the usefulness of endoscopic biopsies from Vater's ampulla and the bile duct to diagnose IgG4-SC.
  • METHODS: The present study included 29 IgG4-SC patients (26 with both pancreatitis and cholangitis, and 3 with cholangitis only), 6 PSC patients, and 27 pancreatobiliary carcinoma patients.
  • All patients underwent endoscopic biopsies from Vater's ampulla and the common bile duct.
  • RESULTS: For the ampullary and bile duct biopsies, the IgG4-SC samples had a significantly greater number of IgG4-positive plasma cells than the PSC or pancreatobiliary carcinoma specimens.
  • The bile duct biopsy was significantly valuable for IgG4-SC patients with swelling of the pancreatic head.
  • [MeSH-major] Ampulla of Vater / pathology. Autoimmune Diseases / immunology. Biopsy / methods. Cholangitis, Sclerosing / immunology. Common Bile Duct / pathology. Immunoglobulin G / immunology. Pancreatitis / immunology
  • [MeSH-minor] Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Humans. Middle Aged. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 20880174.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


63. Nguyen N, Shah JN, Binmoeller KF: Outcomes of endoscopic papillectomy in elderly patients with ampullary adenoma or early carcinoma. Endoscopy; 2010 Nov;42(11):975-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of endoscopic papillectomy in elderly patients with ampullary adenoma or early carcinoma.
  • Outcomes for 14 elderly (age ≥ 70 years) patients (79.4 ± 1.0 years) who underwent endoscopic papillectomy for ampullary tumors were compared with those of 22 younger (age < 70 years) patients (52.5 ± 1.9 years).
  • Whilst all younger patients survived, five elderly patients died but three of these deaths were not cancer-related.
  • Advanced age, therefore, did not adversely influence the outcomes of endoscopic papillectomy, suggesting it may be a treatment of choice for elderly patients with ampullary tumors or early cancer who are deemed unfit for surgery.
  • [MeSH-major] Adenoma, Acidophil / surgery. Ampulla of Vater / surgery. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Endoscopy, Gastrointestinal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21072717.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Kawabata Y, Tanaka T, Nishisaka T, Inao T, Nishi T, Yano S: Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis. Diagn Pathol; 2010;5:75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis.
  • BACKGROUND: We assessed the expression of cytokeratin (CK) and apomucin (MUC) in ampullary carcinoma (AC) to develop a system for the classification of ACs on the basis of their clinical significance.
  • [MeSH-major] Ampulla of Vater / chemistry. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Common Bile Duct Neoplasms / chemistry. Mucin-1 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Disease Progression. Female. Humans. Immunohistochemistry. Japan. Kaplan-Meier Estimate. Keratin-20 / analysis. Male. Middle Aged. Mucin 5AC / analysis. Mucin-6 / analysis. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):346-51 [17097846.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):536-41 [15071739.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3195-201 [17710498.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):695-702 [11345833.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] J Am Coll Surg. 2006 Jan;202(1):112-9 [16377504.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):359-67 [15725805.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):596-607 [10440687.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Surgery. 1997 Jun;121(6):611-7 [9186460.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • (PMID = 21106111.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / MUC1 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-6
  • [Other-IDs] NLM/ PMC3003636
  •  go-up   go-down


65. Tsukada K, Takada T, Miyazaki M, Miyakawa S, Nagino M, Kondo S, Furuse J, Saito H, Tsuyuguchi T, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Amano H, Miura F, Japanese Association of Biliary Surgery, Japanese Society of Hepato-Biliary-Pancreatic Surgery, Japan Society of Clinical Oncology: Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg; 2008;15(1):31-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of biliary tract and ampullary carcinomas.
  • Diagnostic methods for biliary tract carcinoma and the efficacy of these methods are discussed.
  • Neither definite methods for early diagnosis nor specific markers are available in this disease.
  • Diagnoses of extrahepatic bile duct cancer and ampullary carcinoma are often made based on the presence of obstructive jaundice.
  • Although rare, abdominal pain and pyrexia, as well as abnormal findings of the hepatobiliary system detected by hemato-biochemical examination, serve as a clue to making a diagnosis of these diseases.
  • On the other hand, the early diagnosis of gallbladder cancer is scarcely possible on the basis of clinical symptoms, so when this cancer is found with the onset of abdominal pain and jaundice, it is already advanced at the time of detection, thus making a cure difficult.
  • When gallbladder cancer is suspected, enhanced CT is carried out.
  • However, direct biliary tract imaging is necessary for making a precise diagnosis of the horizontal extension of bile duct cancer.
  • [MeSH-major] Ampulla of Vater. Biliary Tract Neoplasms / diagnosis. Carcinoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2006 May;38(5):521-5 [16767591.001]
  • [Cites] J Hepatol. 2006 Jul;45(1):43-50 [16690156.001]
  • [Cites] World J Surg. 2007 Jan;31(1):155-61; discussion 162-3 [17180477.001]
  • [Cites] Gastrointest Endosc. 2007 Oct;66(4):730-6 [17905015.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):2-6 [18274838.001]
  • [Cites] Radiology. 2001 Jul;220(1):90-6 [11425978.001]
  • [Cites] AJR Am J Roentgenol. 2001 Nov;177(5):1095-100 [11641179.001]
  • [Cites] Radiographics. 2002 Jan-Feb;22(1):173-87 [11796906.001]
  • [Cites] Trop Gastroenterol. 2001 Oct-Dec;22(4):227-9 [11963335.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):405-10 [12016370.001]
  • [Cites] AJR Am J Roentgenol. 2002 Aug;179(2):423-8 [12130444.001]
  • [Cites] Eur Radiol. 2002 Aug;12(8):1993-9 [12136317.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6 Suppl):S206-12 [12447269.001]
  • [Cites] J Magn Reson Imaging. 2002 Dec;16(6):676-84 [12451581.001]
  • [Cites] World J Surg. 2003 Mar;27(3):260-5 [12607048.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):167-76 [12623362.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Aug;18(8):950-3 [12859725.001]
  • [Cites] Gastrointest Endosc. 2003 Oct;58(4):536-41 [14520286.001]
  • [Cites] Ann Intern Med. 2003 Oct 7;139(7):547-57 [14530225.001]
  • [Cites] Semin Gastrointest Dis. 2003 Oct;14(4):208-21 [14719771.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):90-7 [14746840.001]
  • [Cites] Oncology (Williston Park). 2004 Jun;18(7):889-96 [15255172.001]
  • [Cites] Radiology. 2004 Oct;233(1):234-40 [15333766.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):739-43 [16082591.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):374-82 [16111955.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Br J Surg. 2000 Jan;87(1):110-5 [10606921.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] Gut. 2000 Feb;46(2):250-4 [10644321.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6):786-94 [11084070.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):65-70 [11248179.001]
  • [Cites] Gastrointest Endosc. 2001 Mar;53(3):300-7 [11231387.001]
  • [Cites] Hepatology. 2001 May;33(5):1029-35 [11343227.001]
  • [Cites] J Clin Gastroenterol. 2006 Feb;40(2):162-6 [16394879.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1580-6 [16714646.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):665-9 [16724349.001]
  • [Cites] Ann Surg. 1982 May;195(5):624-31 [7073360.001]
  • [Cites] Acta Cytol. 1982 May-Jun;26(3):311-6 [6285653.001]
  • [Cites] Acta Cytol. 1988 Jul-Aug;32(4):475-81 [3400385.001]
  • [Cites] Radiology. 1989 Jul;172(1):35-40 [2544924.001]
  • [Cites] Radiology. 1989 Sep;172(3):689-92 [2549565.001]
  • [Cites] Endoscopy. 1989 Dec;21 Suppl 1:351-6 [2606085.001]
  • [Cites] Surg Clin North Am. 1990 Dec;70(6):1429-47 [2174191.001]
  • [Cites] Gastrointest Endosc. 1990 Nov-Dec;36(6):588-92 [2279648.001]
  • [Cites] J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):97-102 [2092159.001]
  • [Cites] Anticancer Res. 1992 Sep-Oct;12(5):1687-93 [1332581.001]
  • [Cites] Endoscopy. 1993 Jan;25(1):76-80 [8384103.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • [Cites] Radiology. 1993 Dec;189(3):875-80 [8234719.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2922-9 [8199989.001]
  • [Cites] Acta Cytol. 1995 May-Jun;39(3):494-8 [7762339.001]
  • [Cites] Endoscopy. 1995 Oct;27(8):579-83 [8608750.001]
  • [Cites] Radiology. 1996 Mar;198(3):869-73 [8628885.001]
  • [Cites] Hepatogastroenterology. 1996 Jan-Feb;43(7):260-7 [8682475.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):195-201 [8661547.001]
  • [Cites] Gastrointest Endosc. 1997 Mar;45(3):251-60 [9087831.001]
  • [Cites] Hepatogastroenterology. 1997 Sep-Oct;44(17):1477-83 [9356876.001]
  • [Cites] Gastroenterologist. 1997 Dec;5(4):306-15 [9436006.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):405-11 [9527064.001]
  • [Cites] Arch Surg. 1998 Jul;133(7):735-9 [9688001.001]
  • [Cites] Gastrointest Endosc. 1998 Oct;48(4):406-10 [9786115.001]
  • [Cites] Gastrointest Endosc. 1999 Mar;49(3 Pt 1):349-57 [10049419.001]
  • [Cites] Br J Radiol. 1998 Dec;71(852):1279-82 [10319001.001]
  • [Cites] N Engl J Med. 1999 Jul 22;341(4):258-64 [10413739.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):5-7 [15782981.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Apr 15;21(8):933-48 [15813829.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • (PMID = 18274842.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2794353
  • [Investigator] Kai M; Kimura Y; Sawada S; Shimizu H; Nakagawara H; Nakachi K; Yoshitome H; Saisyo H; Ryu M; Shikata S; Nimura Y
  •  go-up   go-down


66. Dai YC, Ho CL, Tsai YC, Hsu YH, Chang YC, Liu HS, Chen HH, Chow NH: Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval. J Cancer Res Clin Oncol; 2005 Feb;131(2):94-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval.
  • PURPOSE: The genetic basis for gastrointestinal and ampullary carcinomas remains uncertain.
  • METHODS: We screened the allelic status on 16 chromosomal arms in a patient with synchronous ampullary carcinoma and gastric cancer, but who had no family history of familial cancer syndrome.
  • The significance of the shared 14q deletion was examined on clinical cohorts of sporadic gastric (n=12) and ampullary (n=10) carcinoma, respectively.
  • RESULTS: The synchronous gastric and ampullary carcinomas had no frameshift mutations in the APC, MSH2, MSH3, and MSH6 genes.
  • The same allelic loss was also detected in one of ampullary carcinomas (10%) and two of gastric cancers (16.7%).
  • CONCLUSIONS: This study illustrates a paradigm using molecular genetic approach in identifying chromosome 14q32 that may harbor a tumor suppressor gene involved in the pathogenesis of a subset of gastrointestinal and ampullary malignancies.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma / genetics. Chromosomes, Human, Pair 14 / genetics. Common Bile Duct Neoplasms / genetics. Genetic Predisposition to Disease. Loss of Heterozygosity / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Kidney Dis. 1995 May;25(5):694-700 [7747722.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):527-33 [11304572.001]
  • [Cites] J Chir (Paris). 1978 Nov;115(11):623-6 [748356.001]
  • [Cites] Oncology. 1999 Jul;57(1):42-9 [10394124.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jun;111(2):161-5 [10347556.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):45-51 [1309309.001]
  • [Cites] Jpn J Cancer Res. 1995 Jun;86(6):511-5 [7622413.001]
  • [Cites] Oncology. 2001;60(2):151-61 [11244331.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1449-53 [12454776.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):678-83 [10797290.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Gut. 2001 May;48(5):656-9 [11302964.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):35-41 [12072201.001]
  • [Cites] J Pathol. 1998 May;185(1):38-43 [9713358.001]
  • [Cites] S Afr Med J. 1984 Oct 27;66(17):656-8 [6495106.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):748-52 [9973227.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):839-41 [3192328.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2028-32 [10580028.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):655-62 [11159202.001]
  • [Cites] Virchows Arch. 2000 Dec;437(6):605-10 [11193471.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3373-5 [8012952.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):627-31 [10874666.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Feb;21(2):101-7 [9491320.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):177-81 [12127403.001]
  • (PMID = 15503134.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


67. Kim RD, Kundhal PS, McGilvray ID, Cattral MS, Taylor B, Langer B, Grant DR, Zogopoulos G, Shah SA, Greig PD, Gallinger S: Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg; 2006 Jan;202(1):112-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma.
  • BACKGROUND: Complete resection offers the only potential cure for ampullary carcinoma.
  • We analyzed factors that contribute to treatment failure and survival in patients who underwent pancreaticoduodenectomy for ampullary carcinoma.
  • STUDY DESIGN: We retrospectively reviewed all patients who underwent pancreaticoduodenectomy between August 1994 and August 2003 for ampullary carcinoma.
  • CONCLUSIONS: Tumor stage is associated with treatment failure after pancreaticoduodenectomy for ampullary carcinoma and may identify candidates for adjuvant therapy.
  • Because an aggressive surgical approach can be adopted safely with the best chance for cure, we recommend that pancreaticoduodenectomy be offered to all patients with ampullary tumors when malignancy or dysplasia is in question.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377504.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Bucher P, Chassot G, Durmishi Y, Ris F, Morel P: Long-term results of surgical treatment of Vater's ampulla neoplasms. Hepatogastroenterology; 2007 Jun;54(76):1239-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of surgical treatment of Vater's ampulla neoplasms.
  • BACKGROUND/AIMS: Vater's ampulla neoplasms account for 30% of resected bilio-pancreatic confluent tumors.
  • Study aim was to review long-term results of surgical treatment for ampullary neoplasms.
  • METHODOLOGY: A retrospective review from 1993 to 2002 identified 55 patients admitted for Vater's ampulla neoplasm in our institution.
  • RESULTS: Among the ampullary neoplasms, 10 were adenomas (median age 71) and 45 adenocarcinomas (median age 69).
  • The resectability rate of ampullary carcinomas was 84%.
  • CONCLUSIONS: Pancreatoduodenectomy remains the gold standard for Vater's ampulla neoplasms resection due to the low sensitivity of diagnostic biopsies for carcinoma detection.
  • Vater's ampulla neoplasms resection by pancreatoduodenectomy is associated with good long-term results; however survival after curative resection is influenced by lymph node status.
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629078.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


69. Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N: Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol; 2006 Sep;36(9):552-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
  • BACKGROUND: Standard chemotherapy for advanced biliary tract cancer has not been established.
  • The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer.
  • METHODS: Patients with histologically or cytologically confirmed, measurable biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer and ampulla of Vater cancer, which was not amenable to surgery, were eligible for the study.
  • CONCLUSIONS: Combination chemotherapy of UFT and doxorubicin was well tolerated and showed preliminary moderate activity against advanced biliary tract cancer.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887837.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; 1-UFT protocol
  •  go-up   go-down


70. Ruemmele P, Dietmaier W, Terracciano L, Tornillo L, Bataille F, Kaiser A, Wuensch PH, Heinmoeller E, Homayounfar K, Luettges J, Kloeppel G, Sessa F, Edmonston TB, Schneider-Stock R, Klinkhammer-Schalke M, Pauer A, Schick S, Hofstaedter F, Baumhoer D, Hartmann A: Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol; 2009 May;33(5):691-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
  • The prevalence and development of microsatellite instability (MSI) and underlying mismatch repair (MMR) deficiency in the carcinogenesis of adenocarcinomas of the papilla of Vater and their precursor lesions are not well established.
  • We analyzed 120 ampullary adenomas (31 pure adenomas and 89 carcinoma-associated adenomas) and 170 pure adenocarcinomas for MSI, immunohistochemical expression of MMR proteins and specific histopathologic features.
  • Patients with MSI-H carcinoma had a significantly longer overall survival (P=0.0082) than those with MSI-L or MSS tumors.
  • The MMR deficient molecular pathway of carcinogenesis is associated with a histopathologic phenotype in ampullary cancer, similar to the one that has been well described in colon cancer.
  • [MeSH-major] Adenoma / pathology. Ampulla of Vater / pathology. Carcinoma / pathology. Common Bile Duct Neoplasms / pathology. DNA Mismatch Repair. Gene Expression Regulation, Neoplastic. Microsatellite Instability. Precancerous Conditions / pathology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Differentiation. DNA Methylation. DNA-Binding Proteins / genetics. Europe. Female. Gene Deletion. Genotype. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. MutS Homolog 2 Protein / genetics. Neoplasm Invasiveness. Neoplasm Staging. Nuclear Proteins / genetics. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Proportional Hazards Models. Risk Assessment. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252434.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


71. Noh SH, Park DH, Kim YR, Chun YH, Song TJ, Moon SH, Lee SS, Seo DW, Lee SK, Kim MH: Peroral direct cholangioscopic-guided biopsy and photodynamic therapy using an ultraslim upper endoscope for recurrent hepatocellular carcinoma with intraductal tiny nodular tumor growth. Gut Liver; 2010 Sep;4(3):398-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroral direct cholangioscopic-guided biopsy and photodynamic therapy using an ultraslim upper endoscope for recurrent hepatocellular carcinoma with intraductal tiny nodular tumor growth.
  • Bile-duct invasion is rare in patients with hepatocellular carcinoma (HCC).
  • ERCP-guided biopsy failed, and an ampullary stricture was noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981221.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2956356
  • [Keywords] NOTNLM ; Intraductal growth / Peroral direct cholangioscopy / Photodynamic treatment / Recurrent hepatocellular carcinoma
  •  go-up   go-down


72. Park SK, Andreotti G, Sakoda LC, Gao YT, Rashid A, Chen J, Chen BE, Rosenberg PS, Shen MC, Wang BS, Han TQ, Zhang BH, Yeager M, Chanock S, Hsing AW: Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China. Carcinogenesis; 2009 Apr;30(4):606-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary tract cancers, encompassing gallbladder, extrahepatic bile duct and ampulla of Vater cancers, are uncommon but often fatal malignancies.
  • This study included subjects who completed an interview and provided blood, which totaled 411 biliary tract cancer and 893 biliary stone patients and 786 healthy Shanghai residents.
  • The CYP1A1 IVS1 + 606 (rs2606345) T allele was associated with gallbladder [odds ratio (OR) = 2.0, 95% confidence interval (CI), 1.3-3.0] and bile duct cancers (OR = 1.8, 95% CI = 1.1-3.1), whereas the CYP1A1 Ex7 + 131 (rs1048943) G allele was associated with ampulla of Vater cancer (OR = 2.9, 95% CI = 1.5-5.4).
  • After taking into account multiple comparisons for SNPs within each gene, CYP1A1 was significantly associated with gallbladder (P = 0.004) and ampulla of Vater cancers (P = 0.01), but borderline with bile duct cancer (P = 0.06).
  • The effect of CYP1A1 IVS1 + 606 on gallbladder cancer was more pronounced among non-obese (body mass index < 23) (OR = 3.3, 95% CI = 1.8-6.1; P interaction = 0.001).
  • Among women taking oral contraceptives, the effect of SHBG Ex8 + 6 (rs6259) on gallbladder cancer (OR = 6.7, 95% CI = 2.2-20.5; P interaction = 0.001) and stones (OR = 2.3, 95% CI = 1.1-4.9; P-interaction = 0.05) was statistically significant.

  • MedlinePlus Health Information. consumer health - Hormones.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):3-28 [10667460.001]
  • [Cites] Menopause. 2000 May-Jun;7(3):162-7 [10810961.001]
  • [Cites] Pharmacogenetics. 2000 Aug;10(6):519-30 [10975606.001]
  • [Cites] Ann Intern Med. 2001 Oct 2;135(7):493-501 [11578152.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Trends Endocrinol Metab. 2002 Apr;13(3):122-8 [11893526.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):119-24 [12071517.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):762-3 [12115514.001]
  • [Cites] J Endocrinol Invest. 2002 Nov;25(10):893-8 [12508952.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D528-32 [14681474.001]
  • [Cites] Acta Endocrinol Suppl (Copenh). 1980;232:1-127 [6770572.001]
  • [Cites] Recent Prog Horm Res. 1982;38:457-510 [6750727.001]
  • [Cites] J Natl Cancer Inst. 1985 Apr;74(4):741-5 [3857369.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2112-6 [3567872.001]
  • [Cites] Jpn J Cancer Res. 1989 Oct;80(10):932-8 [2515177.001]
  • [Cites] J Clin Epidemiol. 1990;43(7):687-92 [2370576.001]
  • [Cites] J Clin Invest. 1991 Jan;87(1):237-46 [1845870.001]
  • [Cites] Contraception. 1991 Jun;43(6):667-93 [1868737.001]
  • [Cites] J Toxicol Environ Health. 1993 Oct-Nov;40(2-3):309-16 [7901425.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):146-53 [8157350.001]
  • [Cites] Cancer Causes Control. 1994 May;5(3):267-72 [8061176.001]
  • [Cites] Toxicol Lett. 1995 May;77(1-3):357-62 [7618162.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] Eur J Cancer Prev. 1996 Aug;5(4):241-7 [8894561.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:15-22 [9027593.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1132-8 [9262251.001]
  • [Cites] Int J Cancer. 1998 Jan 30;75(3):368-70 [9455795.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):149-52 [9934746.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1529-32 [10430289.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Expert Opin Drug Saf. 2006 Jan;5(1):117-29 [16370961.001]
  • [Cites] J Sex Med. 2006 Jan;3(1):104-13 [16409223.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1591-602 [16397865.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2847-53 [16381022.001]
  • [Cites] Fertil Steril. 2006 May;85(5):1319-40 [16647374.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1251-6 [16361272.001]
  • [Cites] Stat Med. 2006 Sep 30;25(18):3134-49 [16252274.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Nov;21(11):1737-43 [16984599.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1577-82 [18000509.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1849-53 [18076042.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6442-52 [18676870.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):811-5 [18728671.001]
  • (PMID = 19168589.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contraceptives, Oral, Hormonal; 0 / Hormones; 9007-49-2 / DNA; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  • [Other-IDs] NLM/ PMC2664453
  •  go-up   go-down


73. Chen JY, Cai SW, Zhang WZ, Huang XQ, Liu R, Wang J, Chen YL, Ji WB, Shi XJ, Chen MY, Liu ZW, Zhao XQ, Feng YQ, Huang ZQ, Dong JH: [Determinants of long-term survival after pancreaticoduodenectomy for ampulla of Vater carcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Dec 29;89(48):3409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Determinants of long-term survival after pancreaticoduodenectomy for ampulla of Vater carcinoma].
  • OBJECTIVE: To investigate the determinants of long-term survival for ampulla of Vater carcinoma treated by pancreaticoduodenectomy.
  • METHODS: A total of 77 patients with ampulla of Vater carcinoma undergoing pancreaticoduodenectomy were reviewed.
  • Univariate analysis showed that perioperative serum carcinoembryonic antigen (CEA) level (P = 0.012), tumor invasion depth (P = 0.000), UICC stage (P = 0.000) and tumor size (P = 0.001) were significant prognostic factors of ampulla of Vater carcinoma; in multivariate analysis, only the tumor size (P = 0.000) was an independent prognostic factor of ampulla of Vater carcinoma.
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223115.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


74. Hamada Y, Nakayama Y, Mizoguchi M, Ikeda S, Kuroki M, Iwasaki H: MK-1 expression in carcinoma of the ampulla of Vater as a predictor of improved prognosis after surgical resection. Cancer Lett; 2006 Nov 18;243(2):211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MK-1 expression in carcinoma of the ampulla of Vater as a predictor of improved prognosis after surgical resection.
  • This retrospective study investigated the prognostic significance of MK-1 expression in human carcinoma of the ampulla of Vater (CAV).
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Ampulla of Vater. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Female. Humans. Immunohistochemistry / statistics & numerical data. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616808.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human
  •  go-up   go-down


75. Ji JS, Kim HK, Kim SS, Cho YS, Chae HS, Won YD: Periampullary choledochoduodenal fistula associated with ampulla of Vater carcinoma. Dig Dis Sci; 2007 Jun;52(6):1592-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periampullary choledochoduodenal fistula associated with ampulla of Vater carcinoma.
  • [MeSH-major] Biliary Fistula / etiology. Carcinoma / complications. Common Bile Duct Neoplasms / complications. Intestinal Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1983 May;29(2):89-93 [6852486.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(2):179-81 [11455477.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):143-6 [15868079.001]
  • [Cites] Dig Dis Sci. 2001 Nov;46(11):2475-9 [11713956.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2097-100 [9951871.001]
  • (PMID = 17404887.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Blazeby JM, Wilson L, Metcalfe C, Nicklin J, English R, Donovan JL: Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol; 2006 Mar;17(3):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of clinical decision-making in multi-disciplinary cancer teams.
  • Management decisions for patients with cancer are frequently taken within the context of a multi-disciplinary team (MDT).
  • This study evaluated team decision-making in upper gastrointestinal cancer.
  • Consecutive MDT treatment decisions were recorded for patients with oesophageal, gastric, pancreatic and peri-ampullary tumours.
  • Discordant decisions were more frequent for patients with pancreatic or gastric carcinoma as compared to oesophageal cancer (P = 0.001).
  • For upper gastrointestinal cancer, MDTs require more information about co morbid disease and patient choice to truly optimize the implementation of multi-disciplinary expertise.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2006 Aug;17(8):1337-8 [16524967.001]
  • (PMID = 16322114.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Terasawa H, Uchiyama K, Tani M, Kawai M, Tsuji T, Tabuse K, Kobayashi Y, Taniguchi K, Yamaue H: Impact of lymph node metastasis on survival in patients with pathological T1 carcinoma of the ampulla of Vater. J Gastrointest Surg; 2006 Jun;10(6):823-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymph node metastasis on survival in patients with pathological T1 carcinoma of the ampulla of Vater.
  • To determine the prognostic factors for patients with pathological T1 (pT1) carcinoma of the ampulla of Vater, 36 consecutive patients with carcinoma of the ampulla of Vater who underwent surgery were retrospectively analyzed in terms of clinicopathological features.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Common Bile Duct Neoplasms / pathology. Lymphatic Metastasis
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Japan / epidemiology. Lymph Node Excision. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Feb 15;10(4):614-6 [14966929.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Surgery. 2004 Nov;136(5):994-1002 [15523392.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1275-7 [15362731.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):158-63 [15698732.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Arch Surg. 1993 May;128(5):515-20 [8098205.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Arch Surg. 2003 Sep;138(9):941-8; discussion 948-50 [12963649.001]
  • [Cites] Hepatogastroenterology. 1994 Feb;41(1):73-8 [8175122.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Dig Surg. 2003;20(6):511-5 [14506332.001]
  • (PMID = 16769538.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. van Roest MH, Gouw AS, Peeters PM, Porte RJ, Slooff MJ, Fidler V, de Jong KP: Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. Ann Surg; 2008 Jul;248(1):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the impact of perineural growth as a prognostic factor in periampullary adenocarcinoma (pancreatic head, ampulla of Vater, distal bile duct, and duodenal carcinoma).
  • SUMMARY BACKGROUND DATA: Pancreatic head carcinoma is considered to have the worst prognosis of the periampullary carcinomas.
  • RESULTS: Perineural growth was present in 49% of the cases (37 of the 51 patients with pancreatic head carcinoma; 7 of the 30 patients with ampulla of Vater carcinoma; 7 of the 19 with distal bile duct carcinoma; and 8 of the 21 with duodenal carcinoma).
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Peripheral Nerves / pathology. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2009 Mar;249(3):545; author reply 545-6 [19247055.001]
  • (PMID = 18580212.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Foo FJ, Gill U, Verbeke CS, Guthrie JA, Menon KV: Ampullary carcinoma associated with an annular pancreas. JOP; 2007;8(1):50-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary carcinoma associated with an annular pancreas.
  • CASE REPORT: We present a case report of a 78-year-old woman with jaundice due to an ampullary carcinoma associated with an annular pancreas treated by pancreaticoduodenectomy.
  • [MeSH-minor] Aged. Ampulla of Vater / surgery. Female. Humans. Pancreaticoduodenectomy

  • Genetic Alliance. consumer health - Annular Pancreas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228134.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 21
  •  go-up   go-down


80. Casaretto E, Andrada DG, Granero LE: [Results of cephalic pancreaticoduodenectomy for ampullary carcinoma. Analysis of 18 consecutive cases]. Acta Gastroenterol Latinoam; 2010 Mar;40(1):22-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of cephalic pancreaticoduodenectomy for ampullary carcinoma. Analysis of 18 consecutive cases].
  • [Transliterated title] Resultados de la duodenopancreatectomía cefálica en el tratamiento del carcinoma de la ampolla de vater. Análisis de 18 casos consecutivos.
  • BACKGROUND: Complete resection offers the only potential cure for ampullary carcinoma.
  • AIM: The aim of this study was to assess the results of cephalic pancreaticoduodenectomy for patients with ampullary carcinoma based on mortality, hospital morbidity, late morbidity, and survival.
  • PATIENTS AND METHODS: We retrospectively and prospectively reviewed all patients who underwent cephalic pancreaticoduodenectomy, between October 1994 and October 2006 for ampullary carcinoma.
  • CONCLUSIONS: Cephalic pancreaticoduodenectomy is the surgical procedure of choice for ampullary carcinoma, with low hospital mortality, and the best chance for cure in patients with node-negative disease.
  • [MeSH-major] Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Retrospective Studies. Treatment Failure

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446393.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


81. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW: Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • PURPOSE: To evaluate the role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • METHODS AND MATERIALS: Between January 1991 and December 2002, 118 patients with ampulla of Vater cancer underwent en bloc resection.
  • CONCLUSIONS: Adjuvant chemoradiotherapy may enhance locoregional control and overall survival in patients with ampulla of Vater cancer after curative resection, especially in those with nodal involvement.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Irradiation. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394162.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


82. Roh YH, Kim YH, Lee HW, Kim SJ, Roh MS, Jeong JS, Jung GJ: The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology; 2007 Sep;54(78):1641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis.
  • BACKGROUND/AIMS: We wanted to compare the clinicopathological parameters with the immunohistochemical expression patterns and patient survival for the intestinal type (IT) and the pancreatobiliary type (PT) of ampulla of Vater carcinoma.
  • Ampulla of Vater carcinoma can be classified histologically into either IT or PT.
  • METHODOLOGY: From September, 1995, to February, 2004, 34 patients with the pathologic diagnosis of ampulla of Vater carcinoma were retrospectively reviewed and the prognostic factors were analyzed.
  • RESULTS: The 5-year survival rate of the 34 patients with ampulla of Vater carcinoma was 58.8%.
  • A study with a larger number samples would probably elucidate the different clinical course between these two types of ampulla of Vater carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma / pathology. Common Bile Duct Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019683.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 0 / SLC2A1 protein, human
  •  go-up   go-down


83. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS: Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford); 2009 Feb;11(1):18-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).
  • BACKGROUND: In a previous study we reported an 85% R1 rate for pancreatic cancer following the use of the rigorous, fully standardized Leeds Pathology Protocol (LEEPP).
  • METHODS: Clinicopathological features, including exact site and multifocality of margin involvement, and survival were collated from a prospective series of 83 pancreatoduodenectomies for pancreatic (n = 27), ampullary (n = 24) and bile duct cancer (n = 32).
  • RESULTS: The R1 rate was high in pancreatic (82%) and bile duct (72%) cancer and significantly lower in ampullary cancer (25%).
  • Margin status correlated with survival in the entire cohort (P = 0.006) and the pancreatic subgroup (P = 0.046).
  • CONCLUSIONS: Margin involvement in pancreatic cancer is a frequent and prognostically significant finding when specimens are assessed using the LEEPP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Jun;52(7):787-96 [18081813.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1651-60 [18351300.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):75-83; discussion 83 [18209156.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1549-55 [17786531.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):52-60 [17592291.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]
  • [Cites] Pancreas. 2006 Jan;32(1):37-43 [16340742.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(6):402-8 [15619016.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1410-27 [15499648.001]
  • [Cites] Am Surg. 1999 Jul;65(7):618-23; discussion 623-4 [10399969.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Br J Surg. 1996 May;83(5):625-31 [8689203.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):640-5 [8616755.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2118-23 [8104092.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):384-7 [8406311.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Ann Surg. 1986 Jan;203(1):77-81 [3942423.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Pancreas. 2003 Apr;26(3):243-9 [12657950.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] J Gastrointest Surg. 2001 Mar-Apr;5(2):121-30 [11331473.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Chir Ital. 2000 May-Jun;52(3):263-70 [10932371.001]
  • [CommentIn] HPB (Oxford). 2009 Feb;11(1):2-3 [19590617.001]
  • (PMID = 19590619.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2697870
  • [Keywords] NOTNLM ; cancer / margin / pancreas / resection / survival
  •  go-up   go-down


84. Sakata J, Shirai Y, Wakai T, Yokoyama N, Sakata E, Akazawa K, Hatakeyama K: Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol; 2007 Apr;33(3):346-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma.
  • AIM: The nodal status is an established prognostic factor in ampullary carcinoma.
  • METHODS: Of 73 consecutive patients treated for ampullary carcinoma, 62 underwent pancreaticoduodenectomy with regional lymphadenectomy.
  • CONCLUSION: The number, not the location, of positive regional lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097846.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Valeri S, Coppola R, Magistrelli P, Tonini G: Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. Ann Oncol; 2005 Nov;16(11):1847-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972277.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


86. Morris-Stiff G, Teli M, Jardine N, Puntis MC: CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int; 2009 Dec;8(6):620-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
  • This study aimed to evaluate whether CA19-9 levels could accurately differentiate between benign and malignant pancreatobiliary disease.
  • METHODS: All patients referred to a single surgeon for investigation of pancreaticobiliary disease in 2003 in whom a firm diagnosis had been established were included.
  • For malignant disease, a histological diagnosis was required but for benign disease a firm radiological diagnosis was deemed adequate.
  • The patients were divided into 4 categories: pancreatic adenocarcinoma (PCa); cholangiocarcinoma (CCa); chronic pancreatitis (CP) and biliary calculous disease (Calc).
  • RESULTS: Final diagnoses were made of pancreatic adenocarcinoma (PCa, n=73), cholangiocarcinoma (CCa, n=19), ampullary carcinoma (Amp, n=7), neuroendocrine carcinoma (Neu, n=4), duodenal carcinoma (Duo, n=3), chronic pancreatitis (CP, n=115), and biliary calculous disease (Calc, n=27).
  • The CA19-9 levels were significantly greater for malignant than for benign disease, could differentiate PCa from CCa/Duo, and were significantly higher in unresectable than in resectable PCa.
  • A ROC analysis provided an area under the curve for CA19-9 of 0.871 (0.820-0.922), giving an optimal CA19-9 of 70.5 U/ml for differentiating benign from malignant pathology.
  • For benign disease, the CA19-9 correlated directly with the serum bilirubin, but for malignant disease, CA19-9 levels were elevated independent of the bilirubin level.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. CA-19-9 Antigen / blood. Cholelithiasis / diagnosis. Jaundice, Obstructive / etiology. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / diagnosis
  • [MeSH-minor] Alkaline Phosphatase / blood. Bilirubin / blood. Biomarkers / blood. Diagnosis, Differential. Humans. Predictive Value of Tests. ROC Curve. Sensitivity and Specificity


87. Liu N, Liang H, Li Q, Wang DC, Zhang RP, Wang JC, Hao XS: [Determinants of long-term survival in 38 patients with carcinoma of ampulla of Vater treated by local resection]. Zhonghua Zhong Liu Za Zhi; 2005 Oct;27(10):629-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Determinants of long-term survival in 38 patients with carcinoma of ampulla of Vater treated by local resection].
  • OBJECTIVE: To investigate determinants of long-term survival for carcinoma of ampulla of Vater treated by local resection.
  • On deciding for resection, the common bile duct was probe explored which guided the circumferential ring resection 1 cm, away from the tumor, including all layers of duodenum, ampula and partial bile and terminal pancreatic ducts and the posterial wall of duodenum was completed in steps.
  • Meticulous care was taken not to suture the pancreatic duct and endotheliation was ensured at the mouth of common bile duct and duodenum.
  • Preferably it is indicated only in high risk patients with a pT1 and well differentiated ampullary cancer smaller than 1 cm in diameter.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438877.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Ishibashi Y, Ito Y, Omori K, Wakabayashi K: Signet ring cell carcinoma of the ampulla of vater. A case report. JOP; 2009;10(6):690-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet ring cell carcinoma of the ampulla of vater. A case report.
  • CONTEXT: Signet ring cell carcinoma of the ampulla of Vater is extremely rare and only 12 cases have previously been described in the English language literature.
  • We report a case of advanced signet ring cell carcinoma of the ampulla of Vater, with invasion of the duodenum and pancreas.
  • Abdominal computed tomography showed dilatation of the common bile duct and the pancreatic duct.
  • Duodenoscopy indicated an irregularly shaped erosion on the ampulla of Vater.
  • The diagnosis was carcinoma of the ampulla of Vater, and a pancreaticoduodenectomy was performed.
  • The histopathological findings detected signet ring cell carcinoma.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Signet Ring Cell / diagnosis. Common Bile Duct Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890196.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


89. Uchida H, Shibata K, Iwaki K, Kai S, Ohta M, Kitano S: Ampullary cancer and preoperative jaundice: possible indication of the minimal surgery. Hepatogastroenterology; 2009 Jul-Aug;56(93):1194-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary cancer and preoperative jaundice: possible indication of the minimal surgery.
  • BACKGROUND/AIMS: Obstructive jaundice is common symptom of carcinoma of the ampulla of Vater.
  • Preoperative jaundice, serum carbohydrate antigen 19-9 level, pancreatic invasion, lymphatic invasion, venous invasion, perineural invasion, duodenal invasion, margin status, lymph node metastasis, and T stage were shown to be significant prognostic factors.
  • CONCLUSIONS: Preoperative jaundice may reflect advanced-stage in case of ampullary cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / surgery. Jaundice, Obstructive / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760968.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


90. Chung YE, Kim MJ, Park MS, Choi JY, Kim H, Kim SK, Lee M, Kim HJ, Choi JS, Song SY, Kim KW: Differential features of pancreatobiliary- and intestinal-type ampullary carcinomas at MR imaging. Radiology; 2010 Nov;257(2):384-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential features of pancreatobiliary- and intestinal-type ampullary carcinomas at MR imaging.
  • PURPOSE: To define the differential imaging features of pancreatobiliary- and intestinal-type ampullary carcinomas at magnetic resonance (MR) imaging and to correlate these features with pathologic findings.
  • Fifty patients with surgically confirmed ampullary carcinoma and preoperative MR results were included.
  • Two radiologists, blinded to histologic type of cancer, evaluated imaging findings in consensus.
  • Intestinal carcinoma commonly manifested with an oval filling defect at the distal end of the bile duct on MR cholangiopancreatographic (MRCP) images (11 [73%] of 15 vs four [11%] of 35 in pancreatobiliary type) (P < .001).
  • At endoscopy, intestinal carcinoma manifested with an extramural protruding mass (n = 15, 100%) with a papillary surface (n = 11, 73%), whereas pancreatobiliary carcinoma manifested with intramural protruding (n = 5, 28%) or ulcerating (n = 1, 6%) gross morphologic features (P = .047) with a nonpapillary surface (n = 17, 94%) (P < .001).
  • Multiple logistic regression analysis showed that an oval filling defect at the distal end of the bile duct was the only independent finding for differentiating intestinal from pancreatobiliary carcinoma (P = .027).
  • CONCLUSION: An oval filling defect at the distal end of the bile duct on MRCP images and an extramural protruding appearance with a papillary surface at endoscopy are likely to suggest intestinal ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiopancreatography, Magnetic Resonance / methods. Common Bile Duct Neoplasms / diagnosis. Duodenal Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Logistic Models. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010.
  • (PMID = 20829529.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Aksoy M, Sumer A, Sari S, Mete O, Salmaslioglu A, Erbil Y: Pancreatic ampullary carcinoma with neck metastases: a case report. Cases J; 2009;2:146
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ampullary carcinoma with neck metastases: a case report.
  • CASE REPORT: She was diagnosed of ampullary carcinoma for which pancreatoduodenectomy was performed 14 months ago.
  • Histopathological examination revealed the metastasis of the precedent ampullary adenocarcinoma.
  • CONCLUSION: Surgery does not improve survival for advanced metastatic ampullary cancer however, it can be mandatory in specific conditions as our patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1980 Oct;94(10):1205-9 [7430780.001]
  • [Cites] Cancer. 2002 May 15;94(10):2766-92 [12173348.001]
  • [Cites] Pancreatology. 2006;6(4):306-8 [16636605.001]
  • [Cites] Eur J Surg Oncol. 2009 Feb;35(2):187-91 [18343082.001]
  • [Cites] Pancreas. 2007 Jan;34(1):161-4 [17198200.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):187-200 [17245171.001]
  • [Cites] Indian J Cancer. 2007 Jul-Sep;44(3):111-4 [18250533.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Oct;33(10):1505-9 [17033248.001]
  • (PMID = 19946517.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783102
  •  go-up   go-down


92. Schneider AR, Seifert H, Trojan J, Stein J, Hoepffner NM: Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study. Z Gastroenterol; 2005 Oct;43(10):1123-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study.
  • BACKGROUND: Epithelial tumors of the papilla of Vater are rare neoplasms of the gastrointestinal tract.
  • The carcinogenesis of these tumors seems to be fairly analogous to the genetic mechanisms which have been described for colorectal carcinoma.
  • Data on whether the prevalence of colorectal tumors is increased in patients with sporadic ampullary neoplasms are scarce.
  • METHODS: 26 consecutive patients (16 women, 10 men; median age 59 years) with sporadic adenomas (n = 19) or adenocarcinomas (n = 7) of the ampulla of Vater were retrospectively evaluated.
  • Overall, 16 polyps were found among patients with ampullary tumors and 40 in asymptomatic controls (p > 0.05).
  • Colonoscopy detected rectal carcinoma in 2 patients (8%) of the study group.
  • Patients with and without colorectal polyps differed neither significantly by age nor by ampullary histological findings.
  • 50% of the colonic polyps in patients with ampullary neoplasms were located in the ascending colon.
  • CONCLUSIONS: The frequency of colorectal polyps in patients with ampullary tumors did not exceed the risk in the control group.
  • However, the finding of 2 rectal carcinomas among patients with ampullary neoplasms supports the place of screening colonoscopy for the diagnostic work-up of ampullary tumors.
  • [MeSH-major] Adenocarcinoma / complications. Adenoma / complications. Ampulla of Vater. Common Bile Duct Neoplasms / complications. Intestinal Polyps / epidemiology
  • [MeSH-minor] Adenoma, Villous / complications. Adenoma, Villous / surgery. Adenomatous Polyposis Coli / epidemiology. Adult. Aged. Aged, 80 and over. Colonic Polyps / diagnosis. Colonic Polyps / epidemiology. Colonoscopy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220451.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Aranha GV, Aaron JM, Shoup M: Critical analysis of a large series of pancreaticogastrostomy after pancreaticoduodenectomy. Arch Surg; 2006 Jun;141(6):574-9; discussion 579-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 4 most common indications for surgery were pancreatic adenocarcinoma (41.3%), ampullary carcinoma (17.0%), duodenal carcinoma (7.2%), and chronic pancreatitis (7.2%).
  • The most common complications were pancreatic fistulae (13.6%), 1 of which was thought to cause 1 of 2 mortalities in this series.
  • Pancreatic fistulae developing after pancreaticogastrostomy were significantly related to a low preoperative alkaline phosphatase level and surgery for nonpancreatic pathologic findings.
  • CONCLUSIONS: Pancreaticogastrostomy is a safe operation associated with low mortality and morbidity rates and a pancreatic fistula rate of 13.6%.
  • It should be considered as a suitable alternative for management of the pancreatic remnant after pancreaticoduodenectomy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Duodenal Neoplasms / surgery. Female. Humans. Length of Stay. Male. Middle Aged. Pancreatic Fistula / etiology. Pancreatic Neoplasms / surgery. Pancreatitis, Chronic / surgery. Retrospective Studies. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785358.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Akatsu T, Aiura K, Takahashi S, Kameyama K, Kitajima M, Kitagawa Y: Recurrent pancreatitis caused by ampullary carcinoma and minor papilla adenoma in familial polyposis: report of a case. Surg Today; 2008;38(5):440-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pancreatitis caused by ampullary carcinoma and minor papilla adenoma in familial polyposis: report of a case.
  • A 58-year-old man who had undergone total colectomy for FAP 18 years earlier was hospitalized for carcinoma arising from the residual rectum.
  • He had severe diabetes mellitus, but had no symptoms of pancreatic exocrine dysfunction.
  • Upper endoscopy showed multiple duodenal adenomas including carcinoma involving the papilla of Vater.
  • To remove these duodenal adenomas and ampullary carcinoma and prevent recurrent pancreatitis, we performed pancreaticoduodenectomy.
  • On pathologic examination, the major duodenal papilla was completely obstructed by the carcinoma, and the minor papilla was also involved by the adenoma.
  • [MeSH-major] Adenocarcinoma / etiology. Adenoma / etiology. Adenomatous Polyposis Coli / complications. Ampulla of Vater. Common Bile Duct Neoplasms / etiology. Pancreatic Neoplasms / etiology. Pancreatitis / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Pancreatic Ducts. Pancreaticoduodenectomy. Recurrence


95. Berberat PO, Künzli BM, Gulbinas A, Ramanauskas T, Kleeff J, Müller MW, Wagner M, Friess H, Büchler MW: An audit of outcomes of a series of periampullary carcinomas. Eur J Surg Oncol; 2009 Feb;35(2):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-pancreatic periampullary carcinoma such as ampullary carcinoma (AmpCA), distal cholangiocellular carcinoma (CholCA) and duodenal carcinoma (DuoCA) have a better prognosis than pancreatic head adenocarcinoma (PanCA).
  • This study describes the outcome and parameters, which predict survival of non-pancreatic periampullary carcinoma after resection.
  • METHODS AND PATIENTS: Data from 148 consecutive patients with non-pancreatic periampullary carcinomas were recorded prospectively between 1993 and 2005 and analyzed using univariate and multivariate models.
  • RESULTS: One hundred thirty-three of 148 (90%) patients were resected for histologically proven non-pancreatic periampullary carcinomas.
  • CONCLUSION: Only T1/T2 ampullary carcinomas have a good prognosis, whereas T3/T4 ampullary tumors show aggressiveness similar to that of pancreatic head adenocarcinomas.
  • [MeSH-major] Ampulla of Vater. Biliary Tract Surgical Procedures / methods. Carcinoma / surgery. Clinical Audit / methods. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343082.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


96. Pancreatric Section, British Society of Gastroenterology, Pancreatic Society of Great Britain and Ireland, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, Royal College of Pathologists, Special Interest Group for Gastro-Intestinal Radiology: Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut; 2005 Jun;54 Suppl 5:v1-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Pancreatic Ductal / therapy. Common Bile Duct Neoplasms / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Cancer Care Facilities / organization & administration. Cancer Care Facilities / standards. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance / methods. Humans. Incidence. Magnetic Resonance Imaging / methods. Medical Audit. Palliative Care / organization & administration. Palliative Care / standards. Stents. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 1993 Jan;38(1):59-64 [8420761.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):104-11; discussion 111-3 [7906097.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):102-7 [7906180.001]
  • [Cites] World J Surg. 1993 Nov-Dec;17(6):796-800 [8109121.001]
  • [Cites] Radiology. 1994 Mar;190(3):745-51 [8115622.001]
  • [Cites] Radiology. 1994 Jun;191(3):741-5 [8184055.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):116-7 [7881927.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2077-82 [7535184.001]
  • [Cites] Radiology. 1995 May;195(2):327-32 [7724748.001]
  • [Cites] AJR Am J Roentgenol. 1995 Apr;164(4):879-84 [7726040.001]
  • [Cites] Gut. 1995 Apr;36(4):618-21 [7537708.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):399-402 [7796024.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):247-51 [7797022.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):403-9 [7638997.001]
  • [Cites] Br J Surg. 1995 Jul;82(7):975-9 [7648124.001]
  • [Cites] Surgery. 1995 Sep;118(3):472-8 [7652681.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):891-904 [7660252.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):969-88 [7544920.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):975-7 [7666917.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):638-45 [7487211.001]
  • [Cites] Nat Genet. 1996 May;13(1):120-2 [8673090.001]
  • [Cites] Am J Gastroenterol. 1996 Jul;91(7):1410-6 [8678005.001]
  • [Cites] Nutrition. 1996 Jan;12(1 Suppl):S27-30 [8850216.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] West J Med. 1996 Nov;165(5):294-300 [8993200.001]
  • [Cites] Abdom Imaging. 1997 Mar-Apr;22(2):199-203 [9013535.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):453-9 [9016226.001]
  • [Cites] Clin Radiol. 1997 Jan;52(1):24-30 [9022576.001]
  • [Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Gastrointest Endosc. 1997 May;45(5):387-93 [9165320.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):237-41 [9324129.001]
  • [Cites] Endoscopy. 1997 Aug;29(6):472-86 [9342565.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1370-6 [9361591.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):139-43 [9423619.001]
  • [Cites] J Clin Gastroenterol. 1998 Mar;26(2):125-9 [9563924.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Br J Surg. 1998 May;85(5):611-7 [9635805.001]
  • [Cites] Radiology. 1998 Aug;208(2):537-42 [9680589.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):429-38 [9742926.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Radiology. 1999 Oct;213(1):107-11 [10540649.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):903-11 [10705012.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):314-27 [10918161.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):26-9; discussion 29-30 [1824810.001]
  • [Cites] Baillieres Clin Gastroenterol. 1990 Dec;4(4):889-916 [2078790.001]
  • [Cites] Baillieres Clin Gastroenterol. 1990 Dec;4(4):931-9 [2078792.001]
  • [Cites] Baillieres Clin Gastroenterol. 1990 Dec;4(4):985-93 [2078795.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):177-85 [2081923.001]
  • [Cites] Cancer. 1991 May 15;67(10):2664-70 [2015568.001]
  • [Cites] Pancreas. 1991 Mar;6(2):127-31 [1886881.001]
  • [Cites] Int J Pancreatol. 1991 Summer;9:153-7 [1720800.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Br J Surg. 1992 Jan;79(1):8-20 [1371087.001]
  • [Cites] Radiology. 1992 Apr;183(1):87-95 [1312736.001]
  • [Cites] Br J Surg. 1992 Feb;79(2):152-5 [1348201.001]
  • [Cites] Radiology. 1992 Jun;183(3):815-8 [1584940.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):1980-2 [1316858.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1721-6 [1317506.001]
  • [Cites] Surg Gynecol Obstet. 1992 Sep;175(3):259-65 [1514162.001]
  • [Cites] Surgery. 1992 Nov;112(5):891-6 [1440241.001]
  • [Cites] Lancet. 1992 Dec 19-26;340(8834-8835):1488-92 [1281903.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1865-70 [11747327.001]
  • [Cites] Curr Oncol Rep. 2002 May;4(3):202-12 [11937010.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):147-57; discussion 157-8 [11992799.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1535-49 [8482467.001]
  • [Cites] Am J Surg. 1993 May;165(5):600-6 [8488945.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] Ann Surg. 1993 May;217(5):447-55; discussion 456-7 [7683868.001]
  • [Cites] Endoscopy. 1993 Feb;25(2):143-50 [8491130.001]
  • [Cites] Br J Surg. 1993 Apr;80(4):414-21 [8495300.001]
  • [Cites] Surg Endosc. 1993 May-Jun;7(3):177-81 [8503074.001]
  • [Cites] Surgery. 1993 Jul;114(1):82-6 [8102817.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1051-2 [7691373.001]
  • [Cites] Br J Surg. 1993 Sep;80(9):1177-9 [8402126.001]
  • [Cites] J Clin Ultrasound. 1993 Nov-Dec;21(9):623-30 [8227392.001]
  • [Cites] Gastrointest Endosc. 1998 Mar;47(3):267-70 [9540881.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Radiology. 1979 Feb;130(2):345-6 [760147.001]
  • [Cites] Radiology. 1980 Feb;134(2):453-9 [7352230.001]
  • [Cites] Mayo Clin Proc. 1980 Sep;55(9):531-6 [6251320.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1945-9 [7427900.001]
  • [Cites] Br Med J. 1980 Dec 13;281(6255):1589-91 [7004559.001]
  • [Cites] Radiology. 1981 Jan;138(1):211-3 [7455085.001]
  • [Cites] Cancer. 1981 Mar 15;47(6 Suppl):1688-97 [6168357.001]
  • [Cites] Surgery. 1982 Feb;91(2):123-33 [6173929.001]
  • [Cites] Ann Surg. 1982 Mar;195(3):274-81 [6277259.001]
  • [Cites] Lancet. 1982 Oct 23;2(8304):896-9 [6126752.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):346-52 [6305473.001]
  • [Cites] Br J Surg. 1983 Sep;70(9):535-8 [6616158.001]
  • [Cites] Ann Surg. 1983 Nov;198(5):605-10 [6639161.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Br J Surg. 1984 May;71(5):371-5 [6372935.001]
  • [Cites] Clin Gastroenterol. 1984 Sep;13(3):763-89 [6386239.001]
  • [Cites] World J Surg. 1984 Dec;8(6):808-21 [6334938.001]
  • [Cites] World J Surg. 1984 Dec;8(6):880-8 [6516431.001]
  • [Cites] Am Surg. 1985 Jan;51(1):42-6 [3966722.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):373-8 [3973648.001]
  • [Cites] Surgery. 1985 Jun;97(6):641-8 [3890241.001]
  • [Cites] J Natl Cancer Inst. 1986 Jan;76(1):49-60 [3455742.001]
  • [Cites] Lancet. 1988 May 21;1(8595):1149-51 [2896968.001]
  • [Cites] Am J Epidemiol. 1988 Aug;128(2):324-36 [3394699.001]
  • [Cites] Br Med J (Clin Res Ed). 1988 Jun 18;296(6638):1715-7 [2456815.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] AJR Am J Roentgenol. 1989 Mar;152(3):487-91 [2783801.001]
  • [Cites] J Surg Oncol. 1989 Mar;40(3):143-51 [2918720.001]
  • [Cites] Br J Surg. 1988 Dec;75(12):1166-8 [2466520.001]
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):122-6; discussion 126-7 [8383381.001]
  • [Cites] Radiology. 1993 Apr;187(1):99-104 [8451443.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Am J Surg. 1986 Jan;151(1):76-80 [2936262.001]
  • [Cites] Br J Radiol. 1986 Feb;59(698):182-3 [3947829.001]
  • [Cites] Am J Psychiatry. 1986 Aug;143(8):982-6 [3524279.001]
  • [Cites] Ann R Coll Surg Engl. 1986 May;68(3):154-8 [3729266.001]
  • [Cites] Br J Surg. 1986 Aug;73(8):647-50 [3742181.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):411-8 [3767476.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):57-62 [2439854.001]
  • [Cites] Lancet. 1987 Dec 19;2(8573):1449-52 [2447457.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):125-33 [2827228.001]
  • [Cites] Am J Surg. 1988 Mar;155(3):411-4 [3278638.001]
  • [Cites] Gastrointest Endosc. 1988 Jan-Feb;34(1):19-22 [3280393.001]
  • [Cites] Ann Surg. 1994 Jan;219(1):18-24 [7507656.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1575-8 [7507785.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):322-8; discussion 328-30 [10493479.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):146-50 [12007953.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3789-93 [12097290.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3130-6 [12118027.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] Am J Psychiatry. 1967 Jun;123(12):1553-62 [4381627.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] Mayo Clin Proc. 1971 Mar;46(3):174-7 [4324182.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Gut. 1977 Apr;18(4):316-41 [324875.001]
  • [Cites] Gut. 1977 Jul;18(7):580-96 [326643.001]
  • [Cites] Ann Surg. 1977 Jul;186(1):42-50 [195543.001]
  • [Cites] Ann Surg. 1977 Dec;186(6):675-80 [603272.001]
  • [Cites] Gastroenterology. 1989 Apr;96(4):1180-6 [2925062.001]
  • [Cites] Langenbecks Arch Chir. 1988;Suppl 2:133-8 [2467149.001]
  • [Cites] Surgery. 1989 May;105(5):645-53 [2650006.001]
  • [Cites] World J Surg. 1988 Oct;12(5):663-70 [3245219.001]
  • [Cites] J Cancer Res Clin Oncol. 1989;115(2):200-2 [2715169.001]
  • [Cites] Lancet. 1989 Jun 17;1(8651):1369-71 [2567382.001]
  • [Cites] Gut. 1989 Aug;30(8):1132-5 [2475392.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Hepatogastroenterology. 1989 Dec;36(6):450-5 [2482241.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Cancer. 1990 May 15;65(10):2207-12 [2189551.001]
  • [Cites] Br J Cancer. 1990 Jun;61(6):932-6 [2372499.001]
  • [Cites] Br J Surg. 1990 Jul;77(7):725-30 [2200555.001]
  • [Cites] Pain. 1990 Jun;41(3):267-71 [1697055.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Oct;12(10):949-64 [9798799.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):38-45 [10030414.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):189-93 [10100785.001]
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):421-6 [10195727.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] J Gastrointest Surg. 1999 Sep-Oct;3(5):496-505 [10482706.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):80-6 [10487616.001]
  • [Cites] Dig Dis Sci. 1999 Jul;44(7):1303-11 [10489910.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):585-9 [7911387.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):786-92 [8206673.001]
  • [Cites] N Engl J Med. 1994 Jul 14;331(2):81-4 [8208269.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2B):657-66 [8010724.001]
  • [Cites] Br J Surg. 1994 Jun;81(6):882-5 [8044610.001]
  • [Cites] BMJ. 1994 Oct 8;309(6959):901-11 [